Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in Leukemia

Retrieve available abstracts of 486 articles:
HTML format

Single Articles

    September 2022
  1. SEMENZATO G, Teramo A, Calabretto G, Gasparini VR, et al
    All that glitters is not LGL Leukemia.
    Leukemia. 2022 Sep 15. pii: 10.1038/s41375-022-01695.
    PubMed     Abstract available

  2. THOMPSON PA, Jiang X, Banerjee P, Basar R, et al
    A phase two study of high dose blinatumomab in Richter's syndrome.
    Leukemia. 2022;36:2228-2232.
    PubMed     Abstract available

  3. CUTHILL KM, Zhang Y, Pepper A, Boelen L, et al
    Identification of proliferative and non-proliferative subpopulations of leukemic cells in CLL.
    Leukemia. 2022;36:2233-2241.
    PubMed     Abstract available

    August 2022
  4. BERGERON BP, Diedrich JD, Zhang Y, Barnett KR, et al
    Epigenomic profiling of glucocorticoid responses identifies cis-regulatory disruptions impacting steroid resistance in childhood acute lymphoblastic leukemia.
    Leukemia. 2022 Aug 26. pii: 10.1038/s41375-022-01685.
    PubMed     Abstract available

  5. KOSCHADE SE, Klann K, Shaid S, Vick B, et al
    Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia.
    Leukemia. 2022 Aug 23. pii: 10.1038/s41375-022-01678.
    PubMed     Abstract available

  6. YEN R, Grasedieck S, Wu A, Lin H, et al
    Identification of key microRNAs as predictive biomarkers of Nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial.
    Leukemia. 2022 Aug 23. pii: 10.1038/s41375-022-01680.
    PubMed     Abstract available

  7. HEHLMANN R, Lauseker M, Voskanyan A, Fabarius A, et al
    Impact of emerging ACA on survival in chronic myeloid leukemia (CML).
    Leukemia. 2022 Aug 23. pii: 10.1038/s41375-022-01681.

  8. ARNIANI S, Pierini V, Pellanera F, Matteucci C, et al
    Chromothripsis is a frequent event and underlies typical genetic changes in early T-cell precursor lymphoblastic leukemia in adults.
    Leukemia. 2022 Aug 16. pii: 10.1038/s41375-022-01671.
    PubMed     Abstract available

  9. DESPREZ C, Riou J, Peterlin P, Marchand T, et al
    Comparison of scoring systems evaluating suitability for intensive chemotherapy in adults with acute myeloid leukemia-a Grand Ouest Against Leukemia (GOAL) study.
    Leukemia. 2022 Aug 12. pii: 10.1038/s41375-022-01677.
    PubMed     Abstract available

  10. KONG W, He L, Zhu J, Bruck O, et al
    An immunity and pyroptosis gene-pair signature predicts overall survival in acute myeloid leukemia.
    Leukemia. 2022 Aug 9. pii: 10.1038/s41375-022-01662.
    PubMed     Abstract available

  11. ZUNA J, Hovorkova L, Krotka J, Koehrmann A, et al
    Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease.
    Leukemia. 2022 Aug 6. pii: 10.1038/s41375-022-01668.
    PubMed     Abstract available

  12. MOSTOFI N, Shaw C, Walter RB, Percival MM, et al
    Evaluating concordance in assessment of ECOG performance status in acute myeloid leukemia patients.
    Leukemia. 2022 Aug 5. pii: 10.1038/s41375-022-01664.

  13. JAHN N, Jahn E, Saadati M, Bullinger L, et al
    Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.
    Leukemia. 2022 Aug 3. pii: 10.1038/s41375-022-01650.
    PubMed     Abstract available

  14. FENG P, Chen D, Wang X, Li Y, et al
    Inhibition of the m(6)A reader IGF2BP2 as a strategy against T-cell acute lymphoblastic leukemia.
    Leukemia. 2022 Aug 1. pii: 10.1038/s41375-022-01651.
    PubMed     Abstract available

  15. MEYER AE, Stelloh C, Pulakanti K, Burns R, et al
    Combinatorial genetics reveals the Dock1-Rac2 axis as a potential target for the treatment of NPM1;Cohesin mutated AML.
    Leukemia. 2022;36:2032-2041.
    PubMed     Abstract available

  16. KONGKIATKAMON S, Terkawi L, Guan Y, Adema V, et al
    Rare germline alterations of myeloperoxidase predispose to myeloid neoplasms.
    Leukemia. 2022;36:2086-2096.
    PubMed     Abstract available

  17. GBADAMOSI MO, Shastri VM, Elsayed AH, Ries R, et al
    A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials.
    Leukemia. 2022;36:2022-2031.
    PubMed     Abstract available

  18. XIANG P, Yang X, Escano L, Dhillon I, et al
    Elucidating the importance and regulation of key enhancers for human MEIS1 expression.
    Leukemia. 2022;36:1980-1989.
    PubMed     Abstract available

    July 2022
  19. SOVERINI S, De Santis S, Martelli M, Monaldi C, et al
    Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia.
    Leukemia. 2022 Jul 30. pii: 10.1038/s41375-022-01660.
    PubMed     Abstract available

  20. ONG JZL, Yokomori R, Wong RWJ, Tan TK, et al
    Requirement for TP73 and genetic alterations originating from its intragenic super-enhancer in adult T-cell leukemia.
    Leukemia. 2022 Jul 30. pii: 10.1038/s41375-022-01655.
    PubMed     Abstract available

  21. ESCUDERO A, Takagi M, Auer F, Friedrich UA, et al
    Clinical and immunophenotypic characteristics of familial leukemia predisposition caused by PAX5 germline variants.
    Leukemia. 2022 Jul 28. pii: 10.1038/s41375-022-01661.

  22. SCHONFELD L, Rinke J, Hinze A, Nagel SN, et al
    ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia.
    Leukemia. 2022 Jul 28. pii: 10.1038/s41375-022-01648.
    PubMed     Abstract available

  23. GROARKE EM, Patel BA, Shalhoub R, Gutierrez-Rodrigues F, et al
    Predictors of clonal evolution and myeloid neoplasia following immunosuppressive therapy in severe aplastic anemia.
    Leukemia. 2022 Jul 27. pii: 10.1038/s41375-022-01636.
    PubMed     Abstract available

  24. JANSSEN JJWM, Lowenberg B, Manz M, Biemond BJ, et al
    Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.
    Leukemia. 2022 Jul 22. pii: 10.1038/s41375-022-01657.
    PubMed     Abstract available

  25. ROHNERT MA, Kramer M, Schadt J, Ensel P, et al
    Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia.
    Leukemia. 2022 Jul 18. pii: 10.1038/s41375-022-01647.
    PubMed     Abstract available

  26. SIGMUND AM, Huang Y, Ruppert AS, Maddocks K, et al
    Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib.
    Leukemia. 2022 Jul 16. pii: 10.1038/s41375-022-01640.

  27. LIU L, Patnana PK, Xie X, Frank D, et al
    GFI1B acts as a metabolic regulator in hematopoiesis and acute myeloid leukemia.
    Leukemia. 2022 Jul 8. pii: 10.1038/s41375-022-01635.
    PubMed     Abstract available

  28. CARRATT SA, Braun TP, Coblentz C, Schonrock Z, et al
    Correction: Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia.
    Leukemia. 2022 Jul 6. pii: 10.1038/s41375-022-01646.

  29. MOKER P, Zur Stadt U, Zimmermann M, Alawi M, et al
    Characterization of IG-MYC-breakpoints and their application for quantitative minimal disease monitoring in high-risk pediatric Burkitt-lymphoma and -leukemia.
    Leukemia. 2022 Jul 5. pii: 10.1038/s41375-022-01626.

  30. FUHRMANN I, Lenk M, Haferlach T, Stengel A, et al
    AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics.
    Leukemia. 2022;36:1939-1942.

  31. SALMON M, White HE, Zizkova H, Gottschalk A, et al
    Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy.
    Leukemia. 2022;36:1879-1886.
    PubMed     Abstract available

  32. WHITE HE, Salmon M, Albano F, Andersen CSA, et al
    Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study.
    Leukemia. 2022;36:1834-1842.
    PubMed     Abstract available

  33. RICHTER-PECHANSKA P, Kunz JB, Rausch T, Erarslan-Uysal B, et al
    Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolution.
    Leukemia. 2022;36:1759-1768.
    PubMed     Abstract available

  34. CHEN L, Zheng Y, Yu K, Chen S, et al
    Changing causes of death in persons with haematological cancers 1975-2016.
    Leukemia. 2022;36:1850-1860.
    PubMed     Abstract available

  35. MAMIDI MK, Mahmud H, Maiti GP, Mendez MT, et al
    Idelalisib activates AKT via increased recruitment of PI3Kdelta/PI3Kbeta to BCR signalosome while reducing PDK1 in post-therapy CLL cells.
    Leukemia. 2022;36:1806-1817.
    PubMed     Abstract available

  36. PIANIGIANI G, Rocchio F, Peruzzi S, Andresen V, et al
    The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein.
    Leukemia. 2022;36:1931-1934.

  37. YANG S, Zhang XS, Gale RP, Huang XJ, et al
    Co-variates associated with outcomes of tyrosine kinase-inhibitor therapy in persons with chronic myeloid leukaemia initially presenting in accelerated phase.
    Leukemia. 2022;36:1818-1824.
    PubMed     Abstract available

  38. SOFI MH, Tian L, Schutt S, Khan I, et al
    Ceramide synthase 6 impacts T-cell allogeneic response and graft-versus-host disease through regulating N-RAS/ERK pathway.
    Leukemia. 2022;36:1907-1915.
    PubMed     Abstract available

  39. KAISRLIKOVA M, Vesela J, Kundrat D, Votavova H, et al
    RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS.
    Leukemia. 2022;36:1898-1906.
    PubMed     Abstract available

  40. MENEZES AC, Jones R, Shrestha A, Nicholson R, et al
    Increased expression of RUNX3 inhibits normal human myeloid development.
    Leukemia. 2022;36:1769-1780.
    PubMed     Abstract available

    June 2022
  41. VON TRESCKOW J, Cramer P, Robrecht S, Langerbeins P, et al
    Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial.
    Leukemia. 2022 Jun 25. pii: 10.1038/s41375-022-01629.

  42. WEI Y, Kanagal-Shamanna R, Zheng H, Bao N, et al
    Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia.
    Leukemia. 2022 Jun 14. pii: 10.1038/s41375-022-01605.
    PubMed     Abstract available

  43. BUENO-COSTA A, Pineyro D, Garcia-Prieto CA, Ortiz-Barahona V, et al
    Remodeling of the m(6)A RNA landscape in the conversion of acute lymphoblastic leukemia cells to macrophages.
    Leukemia. 2022 Jun 9. pii: 10.1038/s41375-022-01621.

  44. PANINA SB, Pei J, Baran N, Tjahjono E, et al
    Novel mitochondria-targeting compounds selectively kill human leukemia cells.
    Leukemia. 2022 Jun 7. pii: 10.1038/s41375-022-01614.
    PubMed     Abstract available

  45. ZARNEGAR-LUMLEY S, Caldwell KJ, Rubnitz JE
    Relapsed acute myeloid leukemia in children and adolescents: current treatment options and future strategies.
    Leukemia. 2022 Jun 6. pii: 10.1038/s41375-022-01619.
    PubMed     Abstract available

  46. ORVAIN C, Othus M, Johal G, Hunault-Berger M, et al
    Evolution of eligibility criteria for non-transplant randomized controlled trials in adults with acute myeloid leukemia.
    Leukemia. 2022 Jun 3. pii: 10.1038/s41375-022-01624.
    PubMed     Abstract available

  47. TOKSVANG LN, Lee SHR, Yang JJ, Schmiegelow K, et al
    Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations.
    Leukemia. 2022 Jun 2. pii: 10.1038/s41375-022-01591.
    PubMed     Abstract available

  48. ZHANG XS, Gale RP, Li ZY, Zhang MY, et al
    Predictive scoring systems for molecular responses in persons with chronic phase chronic myeloid leukemia receiving initial imatinib therapy.
    Leukemia. 2022 Jun 1. pii: 10.1038/s41375-022-01616.
    PubMed     Abstract available

    Evidence supporting that the attribution of first success in use of arsenic for the treatment of leukaemia should be to David Lissauer (1836-1892).
    Leukemia. 2022;36:1697-1698.

  50. CESARO S, Ljungman P, Mikulska M, Hirsch HH, et al
    Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9).
    Leukemia. 2022;36:1467-1480.
    PubMed     Abstract available

  51. LASZLO GS, Orozco JJ, Kehret AR, Lunn MC, et al
    Development of [(211)At]astatine-based anti-CD123 radioimmunotherapy for acute leukemias and other CD123+ malignancies.
    Leukemia. 2022;36:1485-1491.
    PubMed     Abstract available

  52. TRAVAGLINI S, Ottone T, Angelini DF, Fiori V, et al
    CD99 as a novel therapeutic target on leukemic progenitor cells in FLT3-ITD(mut) AML.
    Leukemia. 2022;36:1685-1688.

    May 2022
  53. BRUMMENDORF TH, Cortes JE, Milojkovic D, Gambacorti-Passerini C, et al
    Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial.
    Leukemia. 2022 May 28. pii: 10.1038/s41375-022-01589.
    PubMed     Abstract available

  54. MOSHIRI H, Cabrera Riofrio DA, Lim YJ, Lauhasurayotin S, et al
    Germline PTPN13 mutations in patients with bone marrow failure and acute lymphoblastic leukemia.
    Leukemia. 2022 May 28. pii: 10.1038/s41375-022-01610.

  55. MAN CH, Zeng X, Lam W, Ng TCC, et al
    Regulation of proton partitioning in kinase-activating acute myeloid leukemia and its therapeutic implication.
    Leukemia. 2022 May 27. pii: 10.1038/s41375-022-01606.
    PubMed     Abstract available

  56. VINADO AC, Calvo IA, Cenzano I, Olaverri D, et al
    The bone marrow niche regulates redox and energy balance in MLL::AF9 leukemia stem cells.
    Leukemia. 2022 May 26. pii: 10.1038/s41375-022-01601.
    PubMed     Abstract available

  57. AGATHANGELIDIS A, Chatzidimitriou A, Chatzikonstantinou T, Tresoldi C, et al
    Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL.
    Leukemia. 2022 May 25. pii: 10.1038/s41375-022-01604.
    PubMed     Abstract available

  58. GRIMM J, Bhayadia R, Gack L, Heckl D, et al
    Combining LSD1 and JAK-STAT inhibition targets Down syndrome-associated myeloid leukemia at its core.
    Leukemia. 2022 May 24. pii: 10.1038/s41375-022-01603.

  59. JAKEL H, Taschler M, Jung K, Weinl C, et al
    Inability to phosphorylate Y88 of p27(Kip1) enforces reduced p27 protein levels and accelerates leukemia progression.
    Leukemia. 2022 May 21. pii: 10.1038/s41375-022-01598.
    PubMed     Abstract available

  60. CURTISS BM, VanCampen J, Macaraeg J, Kong GL, et al
    PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia.
    Leukemia. 2022 May 19. pii: 10.1038/s41375-022-01594.
    PubMed     Abstract available

  61. HENGEVELD PJ, Ertem YE, Dubois JMN, Mellink CHM, et al
    Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21(R110).
    Leukemia. 2022 May 18. pii: 10.1038/s41375-022-01600.

  62. OLIVEIRA ML, Veloso A, Garcia EG, Iyer S, et al
    Mutant IL7R collaborates with MYC to induce T-cell acute lymphoblastic leukemia.
    Leukemia. 2022 May 17. pii: 10.1038/s41375-022-01590.
    PubMed     Abstract available

  63. RUSYN L, Reinartz S, Nikiforov A, Mikhael N, et al
    The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia.
    Leukemia. 2022 May 6. pii: 10.1038/s41375-022-01586.
    PubMed     Abstract available

  64. BACCARANI M, Bonifazi F, Soverini S, Castagnetti F, et al
    Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia.
    Leukemia. 2022;36:1227-1236.
    PubMed     Abstract available

  65. KHANLARI M, Yin CC, Takahashi K, Lachowiez C, et al
    Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients.
    Leukemia. 2022;36:1343-1350.
    PubMed     Abstract available

  66. GBYLI R, Song Y, Liu W, Gao Y, et al
    In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2.
    Leukemia. 2022;36:1313-1323.
    PubMed     Abstract available

  67. CAPLAN M, Wittorf KJ, Weber KK, Swenson SA, et al
    Multi-omics reveals mitochondrial metabolism proteins susceptible for drug discovery in AML.
    Leukemia. 2022;36:1296-1305.
    PubMed     Abstract available

  68. BODDICKER NJ, Achenbach SJ, Parikh SA, Kleinstern G, et al
    Associations of history of vaccination and hospitalization due to infection with risk of monoclonal B-cell lymphocytosis.
    Leukemia. 2022;36:1404-1407.

  69. NACHMIAS B, Khan DH, Voisin V, Mer AS, et al
    IPO11 regulates the nuclear import of BZW1/2 and is necessary for AML cells and stem cells.
    Leukemia. 2022;36:1283-1295.
    PubMed     Abstract available

    April 2022
  70. PARDIEU B, Pasanisi J, Ling F, Dal Bello R, et al
    Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia.
    Leukemia. 2022 Apr 26. pii: 10.1038/s41375-022-01573.
    PubMed     Abstract available

  71. JACOBY E, Ghorashian S, Vormoor B, De Moerloose B, et al
    CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study.
    Leukemia. 2022 Apr 25. pii: 10.1038/s41375-022-01546.
    PubMed     Abstract available

  72. PENNESI E, Michels N, Brivio E, van der Velden VHJ, et al
    Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial.
    Leukemia. 2022 Apr 25. pii: 10.1038/s41375-022-01576.
    PubMed     Abstract available

  73. STRANAHAN AW, Berezniuk I, Chakraborty S, Feller F, et al
    Leukotrienes promote stem cell self-renewal and chemoresistance in acute myeloid leukemia.
    Leukemia. 2022 Apr 23. pii: 10.1038/s41375-022-01579.
    PubMed     Abstract available

  74. MASCHMEYER G, Bullinger L, Garcia-Vidal C, Herbrecht R, et al
    Correction: Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplanta
    Leukemia. 2022 Apr 19. pii: 10.1038/s41375-022-01570.

  75. ZARLING LC, Othus M, Sandmaier BM, Milano F, et al
    Utility of the Treatment-Related Mortality (TRM) score to predict outcomes of adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.
    Leukemia. 2022 Apr 19. pii: 10.1038/s41375-022-01574.
    PubMed     Abstract available

  76. LAETSCH TW, Maude SL, Balduzzi A, Rives S, et al
    Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia.
    Leukemia. 2022 Apr 14. pii: 10.1038/s41375-022-01550.
    PubMed     Abstract available

  77. JIMBO K, Nakajima-Takagi Y, Ito T, Koide S, et al
    Immunoglobulin superfamily member 8 maintains myeloid leukemia stem cells through inhibition of beta-catenin degradation.
    Leukemia. 2022 Apr 13. pii: 10.1038/s41375-022-01564.
    PubMed     Abstract available

  78. GHIA EM, Rassenti LZ, Choi MY, Quijada-Alamo M, et al
    High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia.
    Leukemia. 2022 Apr 13. pii: 10.1038/s41375-022-01543.
    PubMed     Abstract available

  79. SASAKI Y, Kantarjian HM, Short NJ, Wang F, et al
    Correction: Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib.
    Leukemia. 2022 Apr 11. pii: 10.1038/s41375-022-01568.

  80. BODAAR K, Yamagata N, Barthe A, Landrigan J, et al
    JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia.
    Leukemia. 2022 Apr 11. pii: 10.1038/s41375-022-01558.
    PubMed     Abstract available

  81. CHEN R, Chen Y, Xiong P, Zheleva D, et al
    Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells.
    Leukemia. 2022 Apr 5. pii: 10.1038/s41375-022-01553.
    PubMed     Abstract available

  82. CLESHAM K, Walf-Vorderwulbecke V, Gasparoli L, Virely C, et al
    Identification of a c-MYB-directed therapeutic for acute myeloid leukemia.
    Leukemia. 2022 Apr 2. pii: 10.1038/s41375-022-01554.
    PubMed     Abstract available

  83. MASCHMEYER G, Bullinger L, Garcia-Vidal C, Herbrecht R, et al
    Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT),
    Leukemia. 2022 Apr 2. pii: 10.1038/s41375-022-01556.
    PubMed     Abstract available

  84. GUNNARSSON R, Yang M, Biloglav A, Lazarevic V, et al
    Single base substitution and insertion/deletion mutational signatures in adult core binding factor acute myeloid leukemia.
    Leukemia. 2022 Apr 1. pii: 10.1038/s41375-022-01552.

  85. BLUEMN T, Schmitz J, Zheng Y, Burns R, et al
    Differential roles of BAF and PBAF subunits, Arid1b and Arid2, in MLL-AF9 leukemogenesis.
    Leukemia. 2022;36:946-955.
    PubMed     Abstract available

  86. WILSON ER, Helton NM, Heath SE, Fulton RS, et al
    Focal disruption of DNA methylation dynamics at enhancers in IDH-mutant AML cells.
    Leukemia. 2022;36:935-945.
    PubMed     Abstract available

  87. RECHER C, Rollig C, Berard E, Bertoli S, et al
    Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries.
    Leukemia. 2022;36:913-922.
    PubMed     Abstract available

    March 2022
  88. DECROOCQ J, Birsen R, Montersino C, Chaskar P, et al
    RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia.
    Leukemia. 2022 Mar 30. pii: 10.1038/s41375-022-01541.
    PubMed     Abstract available

  89. WALSH C, Hunter A, Lasho T, Finke C, et al
    Differential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia.
    Leukemia. 2022 Mar 29. pii: 10.1038/s41375-022-01551.

  90. JENSEN KS, Oskarsson T, Lahteenmaki PM, Flaegstad T, et al
    Temporal changes in incidence of relapse and outcome after relapse of childhood acute lymphoblastic leukemia over three decades; a Nordic population-based cohort study.
    Leukemia. 2022 Mar 21. pii: 10.1038/s41375-022-01540.
    PubMed     Abstract available

  91. RASMUSSEN B, Gohring G, Bernard E, Nilsson L, et al
    "Randomized phase II study of azacitidine +/- lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)".
    Leukemia. 2022 Mar 11. pii: 10.1038/s41375-022-01537.

  92. FOURNIER E, Heiblig M, Lespinasse C, Flandrin-Gresta P, et al
    Molecular heterogeneity and measurable residual disease of rare NPM1 mutations in acute myeloid leukemia: a nationwide experience from the GBMHM study group.
    Leukemia. 2022 Mar 7. pii: 10.1038/s41375-022-01534.

  93. MORETTI S, Abdel-Aziz AK, Ceccacci E, Pallavicini I, et al
    Co-targeting leukemia-initiating cells and leukemia bulk leads to disease eradication.
    Leukemia. 2022 Mar 4. pii: 10.1038/s41375-022-01530.
    PubMed     Abstract available

  94. BALASUBRAMANIAN SK, Azmi AS, Maciejewski J
    Selective inhibition of nuclear export: a promising approach in the shifting treatment paradigms for hematological neoplasms.
    Leukemia. 2022;36:601-612.
    PubMed     Abstract available

  95. CHARLET A, Kappenstein M, Keye P, Klasener K, et al
    The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML.
    Leukemia. 2022;36:701-711.
    PubMed     Abstract available

  96. STAVAST CJ, van Zuijen I, Karkoulia E, Ozcelik A, et al
    The tumor suppressor MIR139 is silenced by POLR2M to promote AML oncogenesis.
    Leukemia. 2022;36:687-700.
    PubMed     Abstract available

  97. LI P, White T, Xie W, Cui W, et al
    AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome.
    Leukemia. 2022;36:664-674.
    PubMed     Abstract available

  98. MOORMAN AV, Barretta E, Butler ER, Ward EJ, et al
    Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study.
    Leukemia. 2022;36:625-636.
    PubMed     Abstract available

  99. DUCHMANN M, Wagner-Ballon O, Boyer T, Cheok M, et al
    Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML.
    Leukemia. 2022;36:656-663.
    PubMed     Abstract available

  100. RAJAN V, Collett K, Woodside R, Prykhozhij SV, et al
    Stress hematopoiesis induces a proliferative advantage in TET2 deficiency.
    Leukemia. 2022;36:809-820.
    PubMed     Abstract available

    February 2022
  101. ZHANG XS, Gale RP, Zhang MJ, Huang XJ, et al
    A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy.
    Leukemia. 2022 Feb 22. pii: 10.1038/s41375-022-01527.
    PubMed     Abstract available

  102. PIYA S, Yang Y, Bhattacharya S, Sharma P, et al
    Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL.
    Leukemia. 2022 Feb 16. pii: 10.1038/s41375-022-01516.
    PubMed     Abstract available

  103. HALPERN AB, Othus M, Alcorn G, Ali Z, et al
    Physician and patient perceptions on randomization of treatment intensity for unfit adults with acute myeloid leukemia and other high-grade myeloid neoplasm.
    Leukemia. 2022 Feb 16. pii: 10.1038/s41375-022-01524.

  104. VACA AM, Ioannou N, Sivina M, Vlachonikola E, et al
    Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures.
    Leukemia. 2022 Feb 11. pii: 10.1038/s41375-022-01519.
    PubMed     Abstract available

  105. SASAKI Y, Kantarjian HM, Short NJ, Wang F, et al
    Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib.
    Leukemia. 2022 Feb 7. pii: 10.1038/s41375-021-01496.
    PubMed     Abstract available

  106. LEE KL, Ko TK, Saw NYL, Javed A, et al
    Validation and refinement of a RUNX1 mutation-associated gene expression signature in blast crisis chronic myeloid leukemia.
    Leukemia. 2022 Feb 4. pii: 10.1038/s41375-022-01508.

  107. ZHANG Z, Lu Y, Qi Y, Xu Y, et al
    CDK19 regulates the proliferation of hematopoietic stem cells and acute myeloid leukemia cells by suppressing p53-mediated transcription of p21.
    Leukemia. 2022 Feb 2. pii: 10.1038/s41375-022-01512.
    PubMed     Abstract available

  108. CHEN X, Fromm JR, Naresh KN
    "Blasts" in myeloid neoplasms - how do we define blasts and how do we incorporate them into diagnostic schema moving forward?
    Leukemia. 2022;36:327-332.

  109. QIAO J, Liang C, Zhao D, Nguyen LXT, et al
    Spred1 deficit promotes treatment resistance and transformation of chronic phase CML.
    Leukemia. 2022;36:492-506.
    PubMed     Abstract available

  110. PERNER F, Schnoeder TM, Xiong Y, Jayavelu AK, et al
    YBX1 mediates translation of oncogenic transcripts to control cell competition in AML.
    Leukemia. 2022;36:426-437.
    PubMed     Abstract available

  111. PULIKKOTTIL AJ, Bamezai S, Ammer T, Mohr F, et al
    TET3 promotes AML growth and epigenetically regulates glucose metabolism and leukemic stem cell associated pathways.
    Leukemia. 2022;36:416-425.
    PubMed     Abstract available

  112. WAWRZYNIECKA PA, Ibrahim L, Gritti G, Pule MA, et al
    Chimeric antigen receptor T cells for gamma-delta T cell malignancies.
    Leukemia. 2022;36:577-579.

  113. CAPPELLI LV, Meggendorfer M, Baer C, Nadarajah N, et al
    Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration.
    Leukemia. 2022;36:394-402.
    PubMed     Abstract available

    January 2022
  114. WEN Z, Finn R, Gao X, Li L, et al
    Tcof1 haploinsufficiency promotes early T cell precursor-like leukemia in Nras(Q61R/+) mice.
    Leukemia. 2022 Jan 26. pii: 10.1038/s41375-022-01510.

  115. KOPMAR NE, Othus M, Gardner KM, Shaw C, et al
    Outcomes based on treatment setting in refractory acute myeloid leukemia and other high-grade myeloid malignancies.
    Leukemia. 2022 Jan 20. pii: 10.1038/s41375-022-01509.

  116. WANG X, Dong Z, Awuah D, Chang WC, et al
    CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia.
    Leukemia. 2022 Jan 18. pii: 10.1038/s41375-021-01477.
    PubMed     Abstract available

  117. KAPLAN ZLR, van Leeuwen N, Posthuma EFM, Visser O, et al
    Improved relative survival in older patients with acute myeloid leukemia over a 30-year period in the Netherlands: a long haul is needed to change nothing into something.
    Leukemia. 2022 Jan 17. pii: 10.1038/s41375-021-01503.

  118. GOODENOUGH CG, Diouf B, Yang W, Sapkota Y, et al
    Association between CEP72 genotype and persistent neuropathy in survivors of childhood acute lymphoblastic leukemia.
    Leukemia. 2022 Jan 4. pii: 10.1038/s41375-021-01484.

  119. SHARMAN JP, Egyed M, Jurczak W, Skarbnik A, et al
    Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia.
    Leukemia. 2022 Jan 1. pii: 10.1038/s41375-021-01485.

  120. DE BEAUCHAMP L, Himonas E, Helgason GV
    Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia.
    Leukemia. 2022;36:1-12.
    PubMed     Abstract available

  121. YANG J, Weisberg EL, Liu X, Magin RS, et al
    Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2.
    Leukemia. 2022;36:210-220.
    PubMed     Abstract available

  122. TRAN TM, Philipp J, Bassi JS, Nibber N, et al
    The RNA-binding protein IGF2BP3 is critical for MLL-AF4-mediated leukemogenesis.
    Leukemia. 2022;36:68-79.
    PubMed     Abstract available

  123. CANDELLI T, Schneider P, Garrido Castro P, Jones LA, et al
    Identification and characterization of relapse-initiating cells in MLL-rearranged infant ALL by single-cell transcriptomics.
    Leukemia. 2022;36:58-67.
    PubMed     Abstract available

  124. TETTAMANTI S, Pievani A, Biondi A, Dotti G, et al
    Catch me if you can: how AML and its niche escape immunotherapy.
    Leukemia. 2022;36:13-22.
    PubMed     Abstract available

  125. LIM TL, Lieberman DB, Davis AR, Loren AW, et al
    Germline POT1 variants can predispose to myeloid and lymphoid neoplasms.
    Leukemia. 2022;36:283-287.

  126. PEGLIASCO J, Hirsch P, Marzac C, Isnard F, et al
    Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms.
    Leukemia. 2022;36:126-137.
    PubMed     Abstract available

  127. PEPPER AGS, Zucchetto A, Norris K, Tissino E, et al
    Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies.
    Leukemia. 2022;36:271-274.

  128. ORAN B, Champlin RE, Wang F, Tanaka T, et al
    Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation.
    Leukemia. 2022;36:257-262.
    PubMed     Abstract available

  129. BOZIC T, Kuo CC, Hapala J, Franzen J, et al
    Investigation of measurable residual disease in acute myeloid leukemia by DNA methylation patterns.
    Leukemia. 2022;36:80-89.
    PubMed     Abstract available

    December 2021
  130. MELLINGHOFF SC, Robrecht S, Mayer L, Weskamm LM, et al
    SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia.
    Leukemia. 2021 Dec 22. pii: 10.1038/s41375-021-01500.

  131. SPOHR C, Poggio T, Andrieux G, Schonberger K, et al
    Gab2 deficiency prevents Flt3-ITD driven acute myeloid leukemia in vivo.
    Leukemia. 2021 Dec 13. pii: 10.1038/s41375-021-01490.
    PubMed     Abstract available

  132. ASSMANN JLJC, Leon LG, Stavast CJ, van den Bogaerdt SE, et al
    miR-181a is a novel player in the STAT3-mediated survival network of TCRalphabeta+ CD8+ T large granular lymphocyte leukemia.
    Leukemia. 2021 Dec 6. pii: 10.1038/s41375-021-01480.
    PubMed     Abstract available

  133. SUNTHANKAR KI, Jenkins MT, Cote CH, Patel SB, et al
    Isocitrate dehydrogenase mutations are associated with altered IL-1beta responses in acute myeloid leukemia.
    Leukemia. 2021 Dec 2. pii: 10.1038/s41375-021-01487.
    PubMed     Abstract available

  134. CHATZIKONSTANTINOU T, Kapetanakis A, Scarfo L, Karakatsoulis G, et al
    COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study.
    Leukemia. 2021;35:3444-3454.
    PubMed     Abstract available

  135. YANG S, Kay NE, Shi M, Ossenkoppele G, et al
    Measurable residual disease testing in chronic lymphocytic leukaemia: hype, hope neither or both?
    Leukemia. 2021;35:3364-3370.

  136. PATEL SB, Nemkov T, Stefanoni D, Benavides GA, et al
    Metabolic alterations mediated by STAT3 promotes drug persistence in CML.
    Leukemia. 2021;35:3371-3382.
    PubMed     Abstract available

  137. STEENSMA DP, Wermke M, Klimek VM, Greenberg PL, et al
    Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms.
    Leukemia. 2021;35:3542-3550.
    PubMed     Abstract available

  138. GEORGIADIS C, Rasaiyaah J, Gkazi SA, Preece R, et al
    Base-edited CAR T cells for combinational therapy against T cell malignancies.
    Leukemia. 2021;35:3466-3481.
    PubMed     Abstract available

    November 2021
  139. JOHNSON DT, Zhou J, Kroll AV, Fang RH, et al
    Acute myeloid leukemia cell membrane-coated nanoparticles for cancer vaccination immunotherapy.
    Leukemia. 2021 Nov 29. pii: 10.1038/s41375-021-01432.
    PubMed     Abstract available

  140. SHIMOMURA Y, Sobue T, Hirabayashi S, Kondo T, et al
    Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia.
    Leukemia. 2021 Nov 24. pii: 10.1038/s41375-021-01474.
    PubMed     Abstract available

  141. HORAK P, Uhrig S, Witzel M, Gil-Farina I, et al
    Publisher Correction: Comprehensive genomic characterization of gene therapy-induced T-cell acute lymphoblastic leukemia.
    Leukemia. 2021 Nov 16. pii: 10.1038/s41375-021-01364.

  142. ROESSNER PM, Seiffert M
    Publisher Correction: T cells in chronic lymphocytic leukemia: guardians or drivers of disease?
    Leukemia. 2021 Nov 16. pii: 10.1038/s41375-021-01362.

  143. WALTER RB, Hochhaus A, Gale RP
    Elihu H. Estey, MD: leukemia expert, statistician, and gentle soul (July 15, 1946-October 8, 2021).
    Leukemia. 2021 Nov 16. pii: 10.1038/s41375-021-01467.

  144. JEON S, de Smith AJ, Li S, Chen M, et al
    Genome-wide trans-ethnic meta-analysis identifies novel susceptibility loci for childhood acute lymphoblastic leukemia.
    Leukemia. 2021 Nov 8. pii: 10.1038/s41375-021-01465.

  145. SPANJAART AM, Ljungman P, de La Camara R, Tridello G, et al
    Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European He
    Leukemia. 2021 Nov 8. pii: 10.1038/s41375-021-01466.

  146. GADI D, Griffith A, Tyekucheva S, Wang Z, et al
    A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia.
    Leukemia. 2021 Nov 6. pii: 10.1038/s41375-021-01441.
    PubMed     Abstract available

  147. CATHELIN S, Sharon D, Subedi A, Cojocari D, et al
    Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia.
    Leukemia. 2021 Nov 6. pii: 10.1038/s41375-021-01468.

  148. YANG M, Pan Z, Huang K, Busche G, et al
    A unique role of p53 haploinsufficiency or loss in the development of acute myeloid leukemia with FLT3-ITD mutation.
    Leukemia. 2021 Nov 3. pii: 10.1038/s41375-021-01452.
    PubMed     Abstract available

  149. KLOOS A, Mintzas K, Winckler L, Gabdoulline R, et al
    Correction: Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia.
    Leukemia. 2021 Nov 2. pii: 10.1038/s41375-021-01459.

  150. BURKE MJ, Devidas M, Chen Z, Salzer WL, et al
    Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232.
    Leukemia. 2021 Nov 1. pii: 10.1038/s41375-021-01460.
    PubMed     Abstract available

  151. BRUFORD EA, Antonescu CR, Carroll AJ, Chinnaiyan A, et al
    HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions.
    Leukemia. 2021;35:3040-3043.
    PubMed     Abstract available

  152. GALE RP, Hochhaus A, Cross NCP, Harrison CJ, et al
    HGNC nomenclature for fusion genes.
    Leukemia. 2021;35:3039.

  153. HU F, Wang Y, Wang WD, Gale RP, et al
    Improving prediction accuracy in acute myeloid leukaemia: micro-environment, immune and metabolic models.
    Leukemia. 2021;35:3073-3077.

  154. FERRER G, Jung B, Chiu PY, Aslam R, et al
    Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL.
    Leukemia. 2021;35:3163-3175.
    PubMed     Abstract available

  155. FURMAN RR, Byrd JC, Owen RG, O'Brien SM, et al
    Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies.
    Leukemia. 2021;35:3201-3211.
    PubMed     Abstract available

  156. FALINI B, Sciabolacci S, Falini L, Brunetti L, et al
    Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field.
    Leukemia. 2021;35:3113-3126.
    PubMed     Abstract available

  157. HIRABAYASHI S, Butler ER, Ohki K, Kiyokawa N, et al
    Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group.
    Leukemia. 2021;35:3272-3277.

  158. DECKER M, Lammens T, Ferster A, Erlacher M, et al
    Functional classification of RUNX1 variants in familial platelet disorder with associated myeloid malignancies.
    Leukemia. 2021;35:3304-3308.

    October 2021
  159. HEGDE S, Gasilina A, Wunderlich M, Lin Y, et al
    Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemia.
    Leukemia. 2021 Oct 28. pii: 10.1038/s41375-021-01455.
    PubMed     Abstract available

  160. VAN DIJK AD, Griffen TL, Qiu YH, Hoff FW, et al
    RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences.
    Leukemia. 2021 Oct 8. pii: 10.1038/s41375-021-01438.
    PubMed     Abstract available

  161. STETSON LC, Balasubramanian D, Ribeiro SP, Stefan T, et al
    Single cell RNA sequencing of AML initiating cells reveals RNA-based evolution during disease progression.
    Leukemia. 2021;35:2799-2812.
    PubMed     Abstract available

  162. GOURVEST M, De Clara E, Wu HC, Touriol C, et al
    A novel leukemic route of mutant NPM1 through nuclear import of the overexpressed long noncoding RNA LONA.
    Leukemia. 2021;35:2784-2798.
    PubMed     Abstract available

  163. LEWIS R, Maurer HC, Singh N, Gonzalez-Menendez I, et al
    CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness.
    Leukemia. 2021;35:2895-2905.
    PubMed     Abstract available

  164. RUPPERT AS, Booth AM, Ding W, Bartlett NL, et al
    Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202.
    Leukemia. 2021;35:2854-2861.
    PubMed     Abstract available

  165. SONG T, Guo Y, Xue Z, Guo Z, et al
    Small-molecule inhibitor targeting the Hsp70-Bim protein-protein interaction in CML cells overcomes BCR-ABL-independent TKI resistance.
    Leukemia. 2021;35:2862-2874.
    PubMed     Abstract available

    September 2021
  166. BLIXT L, Bogdanovic G, Buggert M, Gao Y, et al
    Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients.
    Leukemia. 2021 Sep 25. pii: 10.1038/s41375-021-01424.
    PubMed     Abstract available

  167. SUD A, Law PJ, Houlston RS
    The clinical utility of polygenic risk scores for chronic lymphocytic leukemia.
    Leukemia. 2021 Sep 25. pii: 10.1038/s41375-021-01429.

  168. PAGOVICH OE, Stiles KM, Camilleri AE, Russo AR, et al
    Gene therapy in a murine model of chronic eosinophilic leukemia-not otherwise specified (CEL-NOS).
    Leukemia. 2021 Sep 20. pii: 10.1038/s41375-021-01400.
    PubMed     Abstract available

  169. JAKOBCZYK H, Jiang Y, Debaize L, Soubise B, et al
    ETV6-RUNX1 and RUNX1 directly regulate RAG1 expression: one more step in the understanding of childhood B-cell acute lymphoblastic leukemia leukemogenesis.
    Leukemia. 2021 Sep 17. pii: 10.1038/s41375-021-01409.

  170. TOKSVANG LN, Grell K, Nielsen SN, Nersting J, et al
    DNA-TG and risk of sinusoidal obstruction syndrome in childhood acute lymphoblastic leukemia.
    Leukemia. 2021 Sep 17. pii: 10.1038/s41375-021-01420.

  171. BOUCHER AC, Caldwell KJ, Crispino JD, Flerlage JE, et al
    Clinical and biological aspects of myeloid leukemia in Down syndrome.
    Leukemia. 2021 Sep 13. pii: 10.1038/s41375-021-01414.
    PubMed     Abstract available

  172. TAMAKI K, Morishima S, Suzuki S, Shigenari A, et al
    Full-length HLA sequencing in adult T cell leukemia-lymphoma uncovers multiple gene alterations.
    Leukemia. 2021 Sep 13. pii: 10.1038/s41375-021-01403.

  173. ECKARDT JN, Middeke JM, Riechert S, Schmittmann T, et al
    Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears.
    Leukemia. 2021 Sep 8. pii: 10.1038/s41375-021-01408.
    PubMed     Abstract available

  174. SAYGIN C, Hu E, Zhang P, Sher S, et al
    Correction: Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq.
    Leukemia. 2021 Sep 3. pii: 10.1038/s41375-021-01398.

  175. TAGA T, Tanaka S, Hasegawa D, Terui K, et al
    Correction to: Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome.
    Leukemia. 2021 Sep 1. pii: 10.1038/s41375-021-01397.

  176. ZHAO LP, Schell B, Sebert M, Kim R, et al
    Prevalence of UBA1 mutations in MDS/CMML patients with systemic inflammatory and auto-immune disease.
    Leukemia. 2021;35:2731-2733.

  177. ISSA GC, Ravandi F, DiNardo CD, Jabbour E, et al
    Therapeutic implications of menin inhibition in acute leukemias.
    Leukemia. 2021;35:2482-2495.
    PubMed     Abstract available

  178. GIONFRIDDO I, Brunetti L, Mezzasoma F, Milano F, et al
    Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML.
    Leukemia. 2021;35:2552-2562.
    PubMed     Abstract available

  179. HEYES E, Schmidt L, Manhart G, Eder T, et al
    Identification of gene targets of mutant C/EBPalpha reveals a critical role for MSI2 in CEBPA-mutated AML.
    Leukemia. 2021;35:2526-2538.
    PubMed     Abstract available

  180. ZHAO LP, Boy M, Azoulay C, Clappier E, et al
    Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease.
    Leukemia. 2021;35:2720-2724.

  181. ROLLIG C, Serve H, Noppeney R, Hanoun M, et al
    Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial.
    Leukemia. 2021;35:2517-2525.
    PubMed     Abstract available

  182. AL HINAI ASA, Grob T, Rijken M, Kavelaars FG, et al
    PPM1D mutations appear in complete remission after exposure to chemotherapy without predicting emerging AML relapse.
    Leukemia. 2021;35:2693-2697.

  183. GODWIN CD, Laszlo GS, Fiorenza S, Garling EE, et al
    Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy.
    Leukemia. 2021;35:2496-2507.
    PubMed     Abstract available

    August 2021
  184. NIEDERKORN M, Ishikawa C, M Hueneman K, Bartram J, et al
    The deubiquitinase USP15 modulates cellular redox and is a therapeutic target in acute myeloid leukemia.
    Leukemia. 2021 Aug 31. pii: 10.1038/s41375-021-01394.
    PubMed     Abstract available

  185. YUAN S, Wang X, Hou S, Guo T, et al
    PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression.
    Leukemia. 2021 Aug 31. pii: 10.1038/s41375-021-01392.
    PubMed     Abstract available

  186. RAFIQ S, McKenna SL, Muller S, Tschan MP, et al
    Lysosomes in acute myeloid leukemia: potential therapeutic targets?
    Leukemia. 2021 Aug 30. pii: 10.1038/s41375-021-01388.
    PubMed     Abstract available

  187. OZTURK S, Paul Y, Afzal S, Gil-Farina I, et al
    Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients.
    Leukemia. 2021 Aug 20. pii: 10.1038/s41375-021-01381.
    PubMed     Abstract available

  188. ZHANG XS, Gale RP, Huang XJ, Jiang Q, et al
    Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?
    Leukemia. 2021 Aug 19. pii: 10.1038/s41375-021-01387.
    PubMed     Abstract available

  189. ANDRES-JENSEN L, Grell K, Rank CU, Albertsen BK, et al
    Endothelial dysfunction and thromboembolism in children, adolescents, and young adults with acute lymphoblastic leukemia.
    Leukemia. 2021 Aug 13. pii: 10.1038/s41375-021-01383.
    PubMed     Abstract available

  190. XU Y, Mou J, Wang Y, Zhou W, et al
    Regulatory T cells promote the stemness of leukemia stem cells through IL10 cytokine-related signaling pathway.
    Leukemia. 2021 Aug 11. pii: 10.1038/s41375-021-01375.
    PubMed     Abstract available

  191. YOSHINO S, Tanaka M, Sunami Y, Takahara T, et al
    Trib1 promotes the development of acute myeloid leukemia in a Ts1Cje mouse model of Down syndrome.
    Leukemia. 2021 Aug 11. pii: 10.1038/s41375-021-01384.

  192. TADMOR T, Benjamini O, Braester A, Rahav G, et al
    Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia.
    Leukemia. 2021 Aug 10. pii: 10.1038/s41375-021-01380.

  193. LIU Q, Chan AKN, Chang WH, Yang L, et al
    3-Ketodihydrosphingosine reductase maintains ER homeostasis and unfolded protein response in leukemia.
    Leukemia. 2021 Aug 9. pii: 10.1038/s41375-021-01378.
    PubMed     Abstract available

  194. YAMAUCHI T, Miyawaki K, Semba Y, Takahashi M, et al
    Targeting leukemia-specific dependence on the de novo purine synthesis pathway.
    Leukemia. 2021 Aug 3. pii: 10.1038/s41375-021-01369.
    PubMed     Abstract available

  195. PIKMAN Y, Ocasio-Martinez N, Alexe G, Dimitrov B, et al
    Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy.
    Leukemia. 2021 Aug 2. pii: 10.1038/s41375-021-01361.
    PubMed     Abstract available

  196. BACCARANI M, Gale RP
    Why chronic myeloid leukaemia cannot be cured by tyrosine kinase-inhibitors.
    Leukemia. 2021;35:2199-2204.

  197. POLIVKOVA V, Benesova A, Zizkova H, Koblihova J, et al
    Sensitivity and reliability of DNA-based mutation analysis by allele-specific digital PCR to follow resistant BCR-ABL1-positive cells.
    Leukemia. 2021;35:2419-2423.

  198. RICHTER J, Lubking A, Soderlund S, Lotfi K, et al
    Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI.
    Leukemia. 2021;35:2416-2418.

  199. RACA G, Abdel-Azim H, Yue F, Broach J, et al
    Increased Incidence of IKZF1 deletions and IGH-CRLF2 translocations in B-ALL of Hispanic/Latino children-a novel health disparity.
    Leukemia. 2021;35:2399-2402.

  200. ABDULLA H, Vo A, Shields BJ, Davies TJ, et al
    T-ALL can evolve to oncogene independence.
    Leukemia. 2021;35:2205-2219.
    PubMed     Abstract available

  201. GUILHOT F, Rigal-Huguet F, Guilhot J, Guerci-Bresler AP, et al
    Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.
    Leukemia. 2021;35:2332-2345.
    PubMed     Abstract available

  202. FANG X, Xu S, Zhang Y, Xu J, et al
    Asxl1 C-terminal mutation perturbs neutrophil differentiation in zebrafish.
    Leukemia. 2021;35:2299-2310.
    PubMed     Abstract available

  203. TODISCO G, Creignou M, Galli A, Guglielmelli P, et al
    Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2(P95)-mutated neoplasms.
    Leukemia. 2021;35:2371-2381.
    PubMed     Abstract available

    July 2021
  204. RUCKER FG, Du L, Luck TJ, Benner A, et al
    Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results.
    Leukemia. 2021 Jul 28. pii: 10.1038/s41375-021-01323.
    PubMed     Abstract available

  205. ZHAO XY, Xu ZL, Mo XD, Chen YH, et al
    Preemptive donor-derived anti-CD19 CAR T-cell infusion showed a promising anti-leukemia effect against relapse in MRD-positive B-ALL after allogeneic hematopoietic stem cell transplantation.
    Leukemia. 2021 Jul 20. pii: 10.1038/s41375-021-01351.

  206. KLEINSTERN G, Weinberg JB, Parikh SA, Braggio E, et al
    Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans.
    Leukemia. 2021 Jul 20. pii: 10.1038/s41375-021-01344.
    PubMed     Abstract available

  207. VAN DER WERF I, Wojtuszkiewicz A, Yao H, Sciarrillo R, et al
    Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia.
    Leukemia. 2021 Jul 8. pii: 10.1038/s41375-021-01340.

  208. BOER JM, Valsecchi MG, Hormann FM, Antic Z, et al
    Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study.
    Leukemia. 2021 Jul 1. pii: 10.1038/s41375-021-01333.

  209. MARTELLI AM, Evangelisti C, Paganelli F, Chiarini F, et al
    GSK-3: a multifaceted player in acute leukemias.
    Leukemia. 2021;35:1829-1842.
    PubMed     Abstract available

  210. SEKERES MA, Watts J, Radinoff A, Sangerman MA, et al
    Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.
    Leukemia. 2021;35:2119-2124.

  211. MODVIG S, Hallbook H, Madsen HO, Siitonen S, et al
    Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting.
    Leukemia. 2021;35:1894-1906.
    PubMed     Abstract available

  212. ESTRUCH M, Reckzeh K, Vittori C, Centio A, et al
    Targeted inhibition of cooperative mutation- and therapy-induced AKT activation in AML effectively enhances response to chemotherapy.
    Leukemia. 2021;35:2030-2042.
    PubMed     Abstract available

  213. LIU H, Xuan L, Lin R, Deng L, et al
    A new pre-emptive TKIs strategy for preventing relapse based on BCR/ABL monitoring for Ph+ALL undergoing allo-HCT: a prospective clinical cohort study.
    Leukemia. 2021;35:2054-2063.
    PubMed     Abstract available

  214. TOMII T, Imamura T, Tanaka K, Kato I, et al
    Leukemic cells expressing NCOR1-LYN are sensitive to dasatinib in vivo in a patient-derived xenograft mouse model.
    Leukemia. 2021;35:2092-2096.

  215. RUMMELT C, Gorantla SP, Meggendorfer M, Charlet A, et al
    Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo.
    Leukemia. 2021;35:2017-2029.
    PubMed     Abstract available

  216. NAMBURI S, Broxmeyer HE, Hong CS, Whiteside TL, et al
    DPP4(+) exosomes in AML patients' plasma suppress proliferation of hematopoietic progenitor cells.
    Leukemia. 2021;35:1925-1932.
    PubMed     Abstract available

    June 2021
  217. SIMONETTI G, Mengucci C, Padella A, Fonzi E, et al
    Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations.
    Leukemia. 2021 Jun 30. pii: 10.1038/s41375-021-01318.
    PubMed     Abstract available

  218. THOMAS KR, Allenspach EJ, Camp ND, Wray-Dutra MN, et al
    Activated interleukin-7 receptor signaling drives B-cell acute lymphoblastic leukemia in mice.
    Leukemia. 2021 Jun 30. pii: 10.1038/s41375-021-01326.
    PubMed     Abstract available

  219. TAJ MM, Moorman AV, Hamadeh L, Petit A, et al
    Prognostic value of Oncogenetic mutations in pediatric T Acute Lymphoblastic Leukemia: a comparison of UKALL2003 and FRALLE2000T protocols.
    Leukemia. 2021 Jun 28. pii: 10.1038/s41375-021-01334.

  220. BEHNERT A, Meyer J, Parsa JY, Hechmer A, et al
    Exploring the genetic and epigenetic origins of juvenile myelomonocytic leukemia using newborn screening samples.
    Leukemia. 2021 Jun 28. pii: 10.1038/s41375-021-01331.

  221. RENNEVILLE A, Patnaik MM, Chan O, Padron E, et al
    Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia.
    Leukemia. 2021 Jun 26. pii: 10.1038/s41375-021-01330.
    PubMed     Abstract available

  222. TOKSVANG LN, Grell K, Nersting J, Degn M, et al
    DNA-thioguanine concentration and relapse risk in children and young adults with acute lymphoblastic leukemia: an IPD meta-analysis.
    Leukemia. 2021 Jun 26. pii: 10.1038/s41375-021-01182.
    PubMed     Abstract available

  223. SHORT NJ, Kantarjian H, Jabbour E
    Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms.
    Leukemia. 2021 Jun 25. pii: 10.1038/s41375-021-01277.
    PubMed     Abstract available

  224. WIERDA WG, Rawstron A, Cymbalista F, Badoux X, et al
    Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations.
    Leukemia. 2021 Jun 24. pii: 10.1038/s41375-021-01241.
    PubMed     Abstract available

  225. ABDALLAH MG, Niibori-Nambu A, Morii M, Yokomizo T, et al
    RUNX1-ETO (RUNX1-RUNX1T1) induces myeloid leukemia in mice in an age-dependent manner.
    Leukemia. 2021 Jun 19. pii: 10.1038/s41375-021-01268.

  226. NISHIDA Y, Zhao R, Heese LE, Akiyama H, et al
    Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML.
    Leukemia. 2021 Jun 14. pii: 10.1038/s41375-021-01308.
    PubMed     Abstract available

  227. LI Z, Jiang N, Lim EH, Chin WHN, et al
    Role of transcriptome sequencing in clinical diagnosis of B-cell acute lymphoblastic leukemia.
    Leukemia. 2021 Jun 10. pii: 10.1038/s41375-021-01185.

  228. KANTARJIAN HM, Hughes TP, Larson RA, Kim DW, et al
    Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
    Leukemia. 2021 Jun 9. pii: 10.1038/s41375-021-01306.

  229. DHAKAL B, Patel S, Girnius S, Bachegowda L, et al
    Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era.
    Leukemia. 2021 Jun 5. pii: 10.1038/s41375-021-01304.

  230. WIEDUWILT MJ, Stock W, Advani A, Luger S, et al
    Correction: Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: an
    Leukemia. 2021 Jun 4. pii: 10.1038/s41375-021-01303.

  231. KIM D, Park G, Huuhtanen J, Ghimire B, et al
    STAT3 activation in large granular lymphocyte leukemia is associated with cytokine signaling and DNA hypermethylation.
    Leukemia. 2021 Jun 1. pii: 10.1038/s41375-021-01296.
    PubMed     Abstract available

  232. MAYANSKIY N, Luchkina P, Fedorova N, Lebedin Y, et al
    Seroconversion and dynamics of the anti-SARS-CoV-2 antibody response related to a hospital COVID-19 outbreak among pediatric oncology patients.
    Leukemia. 2021;35:1820-1822.

  233. GURNARI C, Durrani J, Pagliuca S, Kishtagari A, et al
    Novel invariant features of Good syndrome.
    Leukemia. 2021;35:1792-1796.

  234. ARVINDAM US, van Hauten PMM, Schirm D, Schaap N, et al
    A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells.
    Leukemia. 2021;35:1586-1596.
    PubMed     Abstract available

  235. MARTINEZ-CUADRON D, Serrano J, Gil C, Tormo M, et al
    Evolving treatment patterns and outcomes in older patients (>/=60 years) with AML: changing everything to change nothing?
    Leukemia. 2021;35:1571-1585.
    PubMed     Abstract available

  236. ZHANG C, Wang XQ, Zhang RL, Liu F, et al
    Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant.
    Leukemia. 2021;35:1563-1570.
    PubMed     Abstract available

  237. MURRAY HC, Enjeti AK, Kahl RGS, Flanagan HM, et al
    Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia.
    Leukemia. 2021;35:1782-1787.

  238. DE HAAS V, Pieters R, van der Sluijs-Gelling AJ, Zwaan CM, et al
    Flowcytometric evaluation of cerebrospinal fluid in childhood ALL identifies CNS involvement better then conventional cytomorphology.
    Leukemia. 2021;35:1773-1776.

    May 2021
  239. SAYGIN C, Hu E, Zhang P, Sher S, et al
    Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq.
    Leukemia. 2021 May 21. pii: 10.1038/s41375-021-01295.
    PubMed     Abstract available

  240. VAN DER ZWET JCG, Buijs-Gladdines JGCAM, Cordo' V, Debets DO, et al
    MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance.
    Leukemia. 2021 May 18. pii: 10.1038/s41375-021-01291.
    PubMed     Abstract available

  241. JAIN N, Thompson P, Burger J, Ferrajoli A, et al
    Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
    Leukemia. 2021 May 18. pii: 10.1038/s41375-021-01280.
    PubMed     Abstract available

  242. BRECCIA M, Pregno P, Castagnetti F, Bonifacio M, et al
    Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study.
    Leukemia. 2021 May 17. pii: 10.1038/s41375-021-01292.

  243. CARRATT SA, Braun TP, Coblentz C, Schonrock Z, et al
    Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia.
    Leukemia. 2021 May 17. pii: 10.1038/s41375-021-01278.
    PubMed     Abstract available

  244. DOURTHE ME, Rabian F, Yakouben K, Chevillon F, et al
    Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia.
    Leukemia. 2021 May 17. pii: 10.1038/s41375-021-01281.
    PubMed     Abstract available

  245. VAN DER WERF I, Wojtuszkiewicz A, Yao H, Sciarrillo R, et al
    SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia.
    Leukemia. 2021 May 17. pii: 10.1038/s41375-021-01273.

  246. ROEKER LE, Knorr DA, Thompson MC, Nivar M, et al
    COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia.
    Leukemia. 2021 May 13. pii: 10.1038/s41375-021-01270.

  247. HUGHES TP, Clementino NCD, Fominykh M, Lipton JH, et al
    Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update.
    Leukemia. 2021 May 12. pii: 10.1038/s41375-021-01260.
    PubMed     Abstract available

  248. YAMAGATA K, Shino M, Aikawa Y, Fujita S, et al
    Tip60 activates Hoxa9 and Meis1 expression through acetylation of H2A.Z, promoting MLL-AF10 and MLL-ENL acute myeloid leukemia.
    Leukemia. 2021 May 9. pii: 10.1038/s41375-021-01244.
    PubMed     Abstract available

  249. BRAVO-NAVAS S, Yanez L, Romon I, Briz M, et al
    Map of ubiquitin-like post-translational modifications in chronic lymphocytic leukemia. Role of p53 lysine 120 NEDDylation.
    Leukemia. 2021 May 8. pii: 10.1038/s41375-021-01184.

  250. STOMPER J, Rotondo JC, Greve G, Lubbert M, et al
    Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies.
    Leukemia. 2021 May 6. pii: 10.1038/s41375-021-01218.
    PubMed     Abstract available

  251. DAVER N, Alotaibi AS, Bucklein V, Subklewe M, et al
    T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments.
    Leukemia. 2021 May 5. pii: 10.1038/s41375-021-01253.
    PubMed     Abstract available

  252. GREVER M, Andritsos L, Banerji V, Barrientos JC, et al
    Hairy cell leukemia and COVID-19 adaptation of treatment guidelines.
    Leukemia. 2021 May 4. pii: 10.1038/s41375-021-01257.
    PubMed     Abstract available

    Prevention of childhood leukaemia by lifestyle changes.
    Leukemia. 2021;35:1265-1266.

  254. GREAVES M, Cazzaniga V, Ford A
    Can we prevent childhood Leukaemia?
    Leukemia. 2021;35:1258-1264.

  255. BERG JL, Perfler B, Hatzl S, Uhl B, et al
    EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity.
    Leukemia. 2021;35:1521-1526.

  256. LARGEAUD L, Cornillet-Lefebvre P, Hamel JF, Dumas PY, et al
    Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study.
    Leukemia. 2021;35:1291-1300.
    PubMed     Abstract available

    April 2021
  257. KIEHLMEIER S, Rafiee MR, Bakr A, Mika J, et al
    Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia.
    Leukemia. 2021 Apr 28. pii: 10.1038/s41375-021-01235.
    PubMed     Abstract available

  258. BHM JW, Sia KCS, Jones C, Evans K, et al
    Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia.
    Leukemia. 2021 Apr 24. pii: 10.1038/s41375-021-01248.
    PubMed     Abstract available

  259. GUNNARSSON R, Yang M, Olsson-Arvidsson L, Biloglav A, et al
    Single base substitution mutational signatures in pediatric acute myeloid leukemia based on whole genome sequencing.
    Leukemia. 2021 Apr 16. pii: 10.1038/s41375-021-01242.

  260. BROWN PA, Kairalla JA, Hilden JM, Dreyer ZE, et al
    Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631.
    Leukemia. 2021 Apr 12. pii: 10.1038/s41375-021-01245.

  261. CARRENO-TARRAGONA G, Varghese LN, Sebastian E, Galvez E, et al
    A typical acute lymphoblastic leukemia JAK2 variant, R683G, causes an aggressive form of familial thrombocytosis when germline.
    Leukemia. 2021 Apr 12. pii: 10.1038/s41375-021-01239.

  262. MONTALBAN-BRAVO G, Hammond D, DiNardo CD, Konopleva M, et al
    Activity of venetoclax-based therapy in chronic myelomonocytic leukemia.
    Leukemia. 2021 Apr 12. pii: 10.1038/s41375-021-01240.

  263. HSIEH YC, Kirschner K, Copland M
    Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape.
    Leukemia. 2021 Apr 8. pii: 10.1038/s41375-021-01238.
    PubMed     Abstract available

  264. TAMBARO FP, Singh H, Jones E, Rytting M, et al
    Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia.
    Leukemia. 2021 Apr 8. pii: 10.1038/s41375-021-01232.

  265. SCHLEISS C, Carapito R, Fornecker LM, Muller L, et al
    Temporal multiomic modeling reveals a B-cell receptor proliferative program in chronic lymphocytic leukemia.
    Leukemia. 2021 Apr 8. pii: 10.1038/s41375-021-01221.
    PubMed     Abstract available

  266. BATTA K, Bossenbroek HM, Pemmaraju N, Wilks DP, et al
    Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin.
    Leukemia. 2021 Apr 8. pii: 10.1038/s41375-021-01228.

  267. HU GH, Zhao XY, Zuo YX, Chang YJ, et al
    Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy.
    Leukemia. 2021 Apr 6. pii: 10.1038/s41375-021-01236.
    PubMed     Abstract available

  268. MILLER CR, Huang Y, Ruppert AS, Labanowska J, et al
    Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients.
    Leukemia. 2021 Apr 5. pii: 10.1038/s41375-021-01237.

  269. DAVIDS MS, Fisher DC, Tyekucheva S, McDonough M, et al
    A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients.
    Leukemia. 2021;35:1064-1072.
    PubMed     Abstract available

  270. REEDIJK AMJ, Coebergh JWW, de Groot-Kruseman HA, van der Sluis IM, et al
    Progress against childhood and adolescent acute lymphoblastic leukaemia in the Netherlands, 1990-2015.
    Leukemia. 2021;35:1001-1011.
    PubMed     Abstract available

  271. LONTOS K, Yabes JG, Farah RJ, Boyiadzis M, et al
    Impact of upfront chemotherapy on overall survival in isolated myeloid sarcoma.
    Leukemia. 2021;35:1193-1196.

  272. AU YZ, Gu M, De Braekeleer E, Gozdecka M, et al
    KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements.
    Leukemia. 2021;35:1012-1022.
    PubMed     Abstract available

    March 2021
  273. EISENWORT G, Sadovnik I, Keller A, Ivanov D, et al
    Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia.
    Leukemia. 2021 Mar 30. pii: 10.1038/s41375-021-01227.
    PubMed     Abstract available

  274. WIEDUWILT MJ, Stock W, Advani A, Luger S, et al
    Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from
    Leukemia. 2021 Mar 30. pii: 10.1038/s41375-021-01213.
    PubMed     Abstract available

  275. DHAKAL B, Patel S, Girnius S, Bachegowda L, et al
    Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era.
    Leukemia. 2021 Mar 29. pii: 10.1038/s41375-021-01233.

  276. GRANDITS AM, Nguyen CH, Schlerka A, Hackl H, et al
    Downregulation of MTSS1 in acute myeloid leukemia is associated with a poor prognosis, chemotherapy resistance, and disease aggressiveness.
    Leukemia. 2021 Mar 29. pii: 10.1038/s41375-021-01224.
    PubMed     Abstract available

  277. DINARDO CD, Stein EM, Pigneux A, Altman JK, et al
    Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant.
    Leukemia. 2021 Mar 26. pii: 10.1038/s41375-021-01229.

  278. WALTER RB, Ofran Y, Wierzbowska A, Ravandi F, et al
    Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations.
    Leukemia. 2021 Mar 23. pii: 10.1038/s41375-021-01230.
    PubMed     Abstract available

  279. RIVAS JR, Liu Y, Alhakeem SS, Eckenrode JM, et al
    Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia.
    Leukemia. 2021 Mar 17. pii: 10.1038/s41375-021-01217.
    PubMed     Abstract available

  280. LLAO-CID L, Roessner PM, Chapaprieta V, Ozturk S, et al
    EOMES is essential for antitumor activity of CD8(+) T cells in chronic lymphocytic leukemia.
    Leukemia. 2021 Mar 17. pii: 10.1038/s41375-021-01198.
    PubMed     Abstract available

  281. TIACCI E, De Carolis L, Simonetti E, Merluzzi M, et al
    Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial.
    Leukemia. 2021 Mar 17. pii: 10.1038/s41375-021-01210.

  282. DIEDRICH JD, Dong Q, Ferguson DC, Bergeron BP, et al
    Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks.
    Leukemia. 2021 Mar 13. pii: 10.1038/s41375-021-01209.
    PubMed     Abstract available

  283. STANULLA M, Schaeffeler E, Moricke A, Buchmann S, et al
    Hepatic sinusoidal obstruction syndrome and short-term application of 6-thioguanine in pediatric acute lymphoblastic leukemia.
    Leukemia. 2021 Mar 13. pii: 10.1038/s41375-021-01203.
    PubMed     Abstract available

  284. CHAN O, Renneville A, Padron E
    Chronic myelomonocytic leukemia diagnosis and management.
    Leukemia. 2021 Mar 13. pii: 10.1038/s41375-021-01207.
    PubMed     Abstract available

  285. HE X, Feng Z, Ma J, Zhang X, et al
    CAR T cells targeting CD13 controllably induce eradication of acute myeloid leukemia with a single domain antibody switch.
    Leukemia. 2021 Mar 12. pii: 10.1038/s41375-021-01208.

  286. RADICH JP, Hochhaus A, Masszi T, Hellmann A, et al
    Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial.
    Leukemia. 2021 Mar 11. pii: 10.1038/s41375-021-01205.
    PubMed     Abstract available

  287. PERICA K, Flynn J, Curran KJ, Rivere I, et al
    Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia.
    Leukemia. 2021 Mar 8. pii: 10.1038/s41375-021-01196.

  288. YAMATO G, Deguchi T, Terui K, Toki T, et al
    Predictive factors for the development of leukemia in patients with transient abnormal myelopoiesis and Down syndrome.
    Leukemia. 2021 Mar 3. pii: 10.1038/s41375-021-01171.

  289. KAZIANKA L, Staber PB
    Blood cancer driver Musashi-2 as therapeutic target in chronic lymphocytic leukemia.
    Leukemia. 2021 Mar 2. pii: 10.1038/s41375-021-01144.

  290. LARSON RA, Mandrekar SJ, Huebner LJ, Sanford BL, et al
    Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.
    Leukemia. 2021 Mar 2. pii: 10.1038/s41375-021-01179.
    PubMed     Abstract available

  291. BOND J, Krzywon A, Lhermitte L, Roumier C, et al
    A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis.
    Leukemia. 2021;35:724-736.
    PubMed     Abstract available

  292. YOU X, Chang YI, Kong G, Ranheim EA, et al
    Gata2 -77 enhancer regulates adult hematopoietic stem cell survival.
    Leukemia. 2021;35:901-905.

  293. DE-MORGAN A, Meggendorfer M, Haferlach C, Shlush L, et al
    Male predominance in AML is associated with specific preleukemic mutations.
    Leukemia. 2021;35:867-870.

  294. WASS M, Gollner S, Besenbeck B, Schlenk RF, et al
    A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy.
    Leukemia. 2021;35:701-711.
    PubMed     Abstract available

    February 2021
  295. KOVALOVSKY D, Yoon JH, Cyr MG, Simon S, et al
    Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia.
    Leukemia. 2021 Feb 25. pii: 10.1038/s41375-021-01188.
    PubMed     Abstract available

  296. BROWN PA, Kairalla JA, Hilden JM, Dreyer ZE, et al
    FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631.
    Leukemia. 2021 Feb 23. pii: 10.1038/s41375-021-01177.
    PubMed     Abstract available

  297. MAFFEI R, Fiorcari S, Benatti S, Atene CG, et al
    IRF4 modulates the response to BCR activation in chronic lymphocytic leukemia regulating IKAROS and SYK.
    Leukemia. 2021 Feb 23. pii: 10.1038/s41375-021-01178.
    PubMed     Abstract available

  298. VAN DER VELDEN VHJ, Bruggemann M, Cazzaniga G, Scheijen B, et al
    Potential and pitfalls of whole transcriptome-based immunogenetic marker identification in acute lymphoblastic leukemia; a EuroMRD and EuroClonality-NGS Working Group study.
    Leukemia. 2021 Feb 19. pii: 10.1038/s41375-021-01154.

  299. ECTOR GICG, Visser O, Posthuma EFM, Westerweel PE, et al
    Conditional relative survival among adult patients with chronic myeloid leukemia in the tyrosine kinase inhibitor era: a population-based study in the Netherlands.
    Leukemia. 2021 Feb 18. pii: 10.1038/s41375-021-01174.

  300. ROTBAIN EC, Niemann CU, Rostgaard K, da Cunha-Bang C, et al
    Mapping comorbidity in chronic lymphocytic leukemia: impact of individual comorbidities on treatment, mortality, and causes of death.
    Leukemia. 2021 Feb 18. pii: 10.1038/s41375-021-01156.
    PubMed     Abstract available

  301. TAGA T, Tanaka S, Hasegawa D, Terui K, et al
    Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome.
    Leukemia. 2021 Feb 15. pii: 10.1038/s41375-021-01157.
    PubMed     Abstract available

  302. CUCCHI DGJ, Polak TB, Ossenkoppele GJ, Uyl-De Groot CA, et al
    Two decades of targeted therapies in acute myeloid leukemia.
    Leukemia. 2021 Feb 15. pii: 10.1038/s41375-021-01164.
    PubMed     Abstract available

  303. NGUYEN LXT, Zhang B, Hoang DH, Zhao D, et al
    Cytoplasmic DROSHA and non-canonical mechanisms of MiR-155 biogenesis in FLT3-ITD acute myeloid leukemia.
    Leukemia. 2021 Feb 15. pii: 10.1038/s41375-021-01166.
    PubMed     Abstract available

  304. RAPAPORT F, Neelamraju Y, Baslan T, Hassane D, et al
    Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia.
    Leukemia. 2021 Feb 12. pii: 10.1038/s41375-021-01153.

  305. CHUN S, Kim HY, Kim HJ, Koo HH, et al
    Low CtBP2 expression is associated with a stem cell-like signature and adverse clinical outcome in childhood B-cell lymphoblastic leukemia.
    Leukemia. 2021 Feb 12. pii: 10.1038/s41375-021-01151.

  306. WINTER G, Kirschner-Schwabe R, Groeneveld-Krentz S, Escherich G, et al
    Clinical and genetic characteristics of children with acute lymphoblastic leukemia and Li-Fraumeni syndrome.
    Leukemia. 2021 Feb 12. pii: 10.1038/s41375-021-01163.

  307. DEL GALY AS, Marouf A, Raffoux E, Robin M, et al
    Correction to: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality.
    Leukemia. 2021 Feb 9. pii: 10.1038/s41375-020-01112.

  308. PATKAR N, Kakirde C, Shaikh AF, Salve R, et al
    Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML).
    Leukemia. 2021 Feb 8. pii: 10.1038/s41375-021-01131.
    PubMed     Abstract available

  309. LIBBRECHT C, Xie HM, Kingsley MC, Haladyna JN, et al
    Menin is necessary for long term maintenance of meningioma-1 driven leukemia.
    Leukemia. 2021 Feb 4. pii: 10.1038/s41375-021-01146.
    PubMed     Abstract available

  310. ESTEVE J, Giebel S, Labopin M, Czerw T, et al
    Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An anal
    Leukemia. 2021 Feb 4. pii: 10.1038/s41375-021-01135.
    PubMed     Abstract available

  311. BAUMANN T, Moia R, Gaidano G, Delgado J, et al
    Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients.
    Leukemia. 2021 Feb 4. pii: 10.1038/s41375-021-01149.
    PubMed     Abstract available

  312. WEI AH, Ribera JM, Larson RA, Ritchie D, et al
    Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia.
    Leukemia. 2021 Feb 4. pii: 10.1038/s41375-020-01089.
    PubMed     Abstract available

  313. GE Z, Song C, Ding Y, Tan BH, et al
    Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemia.
    Leukemia. 2021 Feb 2. pii: 10.1038/s41375-021-01132.
    PubMed     Abstract available

  314. ROESSNER PM, Llao Cid L, Lupar E, Roider T, et al
    EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4(+) T cells in chronic lymphocytic leukemia.
    Leukemia. 2021 Feb 1. pii: 10.1038/s41375-021-01136.
    PubMed     Abstract available

  315. PAIVA B, Vidriales MB, Sempere A, Tarin F, et al
    Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia.
    Leukemia. 2021 Feb 1. pii: 10.1038/s41375-021-01126.
    PubMed     Abstract available

  316. GANESAN R, Chennupati V, Ramachandran B, Hansen MR, et al
    Selective recruitment of gammadelta T cells by a bispecific antibody for the treatment of acute myeloid leukemia.
    Leukemia. 2021 Feb 1. pii: 10.1038/s41375-021-01122.
    PubMed     Abstract available

  317. NAIR R, Salinas-Illarena A, Baldauf HM
    New strategies to treat AML: novel insights into AML survival pathways and combination therapies.
    Leukemia. 2021;35:299-311.
    PubMed     Abstract available

  318. YANG S, Varghese AM, Sood N, Chiattone C, et al
    Ethnic and geographic diversity of chronic lymphocytic leukaemia.
    Leukemia. 2021;35:433-439.
    PubMed     Abstract available

  319. LE Q, Hadland B, Meshinchi S, Bernstein I, et al
    Notch blockade overcomes endothelial cell-mediated resistance of FLT3/ITD-positive AML progenitors to AC220 treatment.
    Leukemia. 2021;35:601-605.

  320. ZHAO J, Sui P, Wu B, Chen A, et al
    Benzene induces rapid leukemic transformation after prolonged hematotoxicity in a murine model.
    Leukemia. 2021;35:595-600.

  321. GHASEMI R, Struthers H, Wilson ER, Spencer DH, et al
    Contribution of CTCF binding to transcriptional activity at the HOXA locus in NPM1-mutant AML cells.
    Leukemia. 2021;35:404-416.
    PubMed     Abstract available

    January 2021
  322. PALACIOS F, Yan XJ, Ferrer G, Chen SS, et al
    Musashi 2 influences chronic lymphocytic leukemia cell survival and growth making it a potential therapeutic target.
    Leukemia. 2021 Jan 27. pii: 10.1038/s41375-020-01115.
    PubMed     Abstract available

  323. BHATT NS, Baassiri MJ, Liu W, Bhakta N, et al
    Late outcomes in survivors of childhood acute myeloid leukemia: a report from the St. Jude Lifetime Cohort Study.
    Leukemia. 2021 Jan 25. pii: 10.1038/s41375-021-01134.
    PubMed     Abstract available

  324. YI S, Yan Y, Jin M, Xiong W, et al
    High incidence of MYD88 and KMT2D mutations in Chinese with chronic lymphocytic leukemia.
    Leukemia. 2021 Jan 22. pii: 10.1038/s41375-021-01124.

  325. GOEMANS BF, Noort S, Blink M, Wang YD, et al
    Sensitive GATA1 mutation screening reliably identifies neonates with Down syndrome at risk for myeloid leukemia.
    Leukemia. 2021 Jan 22. pii: 10.1038/s41375-021-01128.

  326. BENMEBAREK MR, Cadilha BL, Herrmann M, Lesch S, et al
    A modular and controllable T cell therapy platform for acute myeloid leukemia.
    Leukemia. 2021 Jan 7. pii: 10.1038/s41375-020-01109.
    PubMed     Abstract available

  327. KANTARJIAN HM, Hughes TP, Larson RA, Kim DW, et al
    Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
    Leukemia. 2021 Jan 7. pii: 10.1038/s41375-020-01111.
    PubMed     Abstract available

  328. O'NIONS J, Muir L, Zheng J, Rees-Spear C, et al
    SARS-CoV-2 antibody responses in patients with acute leukaemia.
    Leukemia. 2021;35:289-292.

  329. SWOBODA DM, Ali NA, Chan O, Padron E, et al
    PTPN11 mutations are associated with poor outcomes across myeloid malignancies.
    Leukemia. 2021;35:286-288.

  330. NOFRINI V, Matteucci C, Pellanera F, Gorello P, et al
    Activating somatic and germline TERT promoter variants in myeloid malignancies.
    Leukemia. 2021;35:274-278.

  331. NAGATE Y, Ezoe S, Fujita J, Okuzaki D, et al
    Ectonucleotidase CD39 is highly expressed on ATLL cells and is responsible for their immunosuppressive function.
    Leukemia. 2021;35:107-118.
    PubMed     Abstract available

    December 2020
  332. WALTER RB, Appelbaum FR, Estey EH
    Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia.
    Leukemia. 2020 Dec 16. pii: 10.1038/s41375-020-01110.

  333. TIRADO-GONZALEZ I, Czlonka E, Nevmerzhitskaya A, Soetopo D, et al
    Correction: CRISPR/Cas9-edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC.
    Leukemia. 2020 Dec 1. pii: 10.1038/s41375-020-01071.
    PubMed     Abstract available

  334. DE BARRIOS O, Galaras A, Trincado JL, Azagra A, et al
    HDAC7 is a major contributor in the pathogenesis of infant t(4;11) proB acute lymphoblastic leukemia.
    Leukemia. 2020 Dec 1. pii: 10.1038/s41375-020-01097.

  335. SOVERINI S, Martelli M, Bavaro L, De Benedittis C, et al
    BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS.
    Leukemia. 2020 Dec 1. pii: 10.1038/s41375-020-01098.

  336. VU TT, Stolzel F, Wang KW, Rollig C, et al
    miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia.
    Leukemia. 2020 Dec 1. pii: 10.1038/s41375-020-01095.
    PubMed     Abstract available

  337. BOND DA, Huang Y, Fisher JL, Ruppert AS, et al
    Second cancer incidence in CLL patients receiving BTK inhibitors.
    Leukemia. 2020;34:3197-3205.
    PubMed     Abstract available

  338. PAN J, Tan Y, Deng B, Tong C, et al
    Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r/r B-ALL children.
    Leukemia. 2020;34:3382-3387.

  339. DUN MD, Mannan A, Rigby CJ, Butler S, et al
    Shwachman-Bodian-Diamond syndrome (SBDS) protein is a direct inhibitor of protein phosphatase 2A (PP2A) activity and overexpressed in acute myeloid leukaemia.
    Leukemia. 2020;34:3393-3397.

    November 2020
  340. EMADI A, Kapadia B, Bollino D, Bhandary B, et al
    Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia.
    Leukemia. 2020 Nov 16. pii: 10.1038/s41375-020-01080.
    PubMed     Abstract available

  341. ESTEY E
    New treatments for acute myeloid leukemia: how much has changed?
    Leukemia. 2020 Nov 12. pii: 10.1038/s41375-020-01084.

  342. ADNAN-AWAD S, Kim D, Hohtari H, Javarappa KK, et al
    Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets.
    Leukemia. 2020 Nov 9. pii: 10.1038/s41375-020-01082.
    PubMed     Abstract available

  343. SPORTOLETTI P, Sorcini D, Guzman AG, Reyes JM, et al
    Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice.
    Leukemia. 2020 Nov 6. pii: 10.1038/s41375-020-01075.
    PubMed     Abstract available

  344. ELCHEVA IA, Spiegelman VS
    Targeting RNA-binding proteins in acute and chronic leukemia.
    Leukemia. 2020 Nov 4. pii: 10.1038/s41375-020-01066.
    PubMed     Abstract available

  345. KOMROKJI RS, Ali NA, Sallman D, Padron E, et al
    Characterization of myelodysplastic syndromes (MDS) with T-cell large granular lymphocyte proliferations (LGL).
    Leukemia. 2020;34:3097-3099.

  346. ZHAO H, Deininger MW
    Declaration of Bcr-Abl1 independence.
    Leukemia. 2020;34:2827-2836.

  347. HEUSER M, Palmisiano N, Mantzaris I, Mims A, et al
    Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results.
    Leukemia. 2020;34:2903-2913.
    PubMed     Abstract available

  348. VENKATARAMAN V, Casey KS, Onozato M, Cin PD, et al
    Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy.
    Leukemia. 2020;34:3050-3054.

  349. LIBERT D, Yuan CM, Masih KE, Galera P, et al
    Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy.
    Leukemia. 2020;34:3064-3069.

    October 2020
  350. ZENT CS, Brady MT, Delage C, Strawderman M, et al
    Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma.
    Leukemia. 2020 Oct 30. pii: 10.1038/s41375-020-01074.

  351. CAPO-CHICHI JM, Kagotho E, Nayyar R, Zhao D, et al
    Systemic mastocytosis with acute myeloid leukemia occurs from mutually exclusive clones expressing KIT(D816V) and FLT3-ITD.
    Leukemia. 2020 Oct 26. pii: 10.1038/s41375-020-01073.

  352. PUTZER S, Varghese L, von Jan J, Braun T, et al
    Corrections: Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine.
    Leukemia. 2020 Oct 23. pii: 10.1038/s41375-020-01067.
    PubMed     Abstract available

  353. HASAN MK, Ghia EM, Rassenti LZ, Widhopf GF 2nd, et al
    Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism.
    Leukemia. 2020 Oct 23. pii: 10.1038/s41375-020-01055.
    PubMed     Abstract available

  354. SIVINA M, Xiao L, Kim E, Vaca A, et al
    CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia.
    Leukemia. 2020 Oct 21. pii: 10.1038/s41375-020-01063.
    PubMed     Abstract available

  355. BARNEA SLONIM L, Gao J, Burkart M, Odetola OE, et al
    Therapy-related B-cell acute lymphoblastic leukemia in adults has unique genetic profile with frequent loss of TP53 and inferior outcome.
    Leukemia. 2020 Oct 21. pii: 10.1038/s41375-020-01061.

  356. BRECCIA M, Piciocchi A, De Stefano V, Finazzi G, et al
    COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey.
    Leukemia. 2020;34:2813-2814.

  357. LAI P, Chen X, Qin L, Jiang Z, et al
    The efficacy and safety of CAR-T cell therapy in patients with refractory ALL and concomitant HBV infection.
    Leukemia. 2020;34:2790-2793.

  358. WANG Y, Liu Y, Tan X, Pan B, et al
    Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection.
    Leukemia. 2020;34:2704-2707.
    PubMed     Abstract available

  359. MYBURGH R, Kiefer JD, Russkamp NF, Magnani CF, et al
    Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells.
    Leukemia. 2020;34:2688-2703.
    PubMed     Abstract available

    September 2020
  360. ECTOR GICG, Visser O, Westerweel PE, Janssen JJWM, et al
    Correction: Primary therapy and relative survival among elderly patients with chronic myeloid leukemia: a population-based study in the Netherlands, 1989-2017.
    Leukemia. 2020 Sep 28. pii: 10.1038/s41375-020-01040.
    PubMed     Abstract available

  361. KATTIH B, Shirvani A, Klement P, Garrido AM, et al
    IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction-a retrospective propensity score analysis.
    Leukemia. 2020 Sep 18. pii: 10.1038/s41375-020-01043.
    PubMed     Abstract available

  362. LETESTU R, Dahmani A, Boubaya M, Baseggio L, et al
    Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia.
    Leukemia. 2020 Sep 15. pii: 10.1038/s41375-020-01009.
    PubMed     Abstract available

  363. JUNCO JJ, Chen T, Rashid R, Terrell M, et al
    An Mb1-Cre-driven oncogenic Kras mutation results in a mouse model of T-acute lymphoblastic leukemia/lymphoma with short latency and high penetrance.
    Leukemia. 2020 Sep 11. pii: 10.1038/s41375-020-01036.

  364. REDA G, Noto A, Cassin R, Zamprogna G, et al
    Reply to "CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report" Analysis of six hematological centers in Lombardy : On behalf of CLL commission of Lombardy Hematology Network (REL).
    Leukemia. 2020;34:2531-2532.

  365. ECTOR GICG, Huijskens EGW, Blijlevens NMA, Westerweel PE, et al
    Prevalence of COVID-19 diagnosis in Dutch CML patients during the 2020 SARS-CoV2 pandemic. A prospective cohort study.
    Leukemia. 2020;34:2533-2535.

  366. QIU Y, Huang S
    CTCF-mediated genome organization and leukemogenesis.
    Leukemia. 2020;34:2295-2304.
    PubMed     Abstract available

  367. KAYSER S, Rahme R, Martinez-Cuadron D, Ghiaur G, et al
    Outcome of older (>/=70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study.
    Leukemia. 2020;34:2333-2341.
    PubMed     Abstract available

    August 2020
  368. ROEKER LE, Knorr DA, Pessin MS, Ramanathan LV, et al
    Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia.
    Leukemia. 2020 Aug 27. pii: 10.1038/s41375-020-01030.

  369. VON WENSERSKI L, Schultheiss C, Bolz S, Schliffke S, et al
    SLAMF receptors negatively regulate B cell receptor signaling in chronic lymphocytic leukemia via recruitment of prohibitin-2.
    Leukemia. 2020 Aug 21. pii: 10.1038/s41375-020-01025.
    PubMed     Abstract available

  370. ADNAN AWAD S, Dufva O, Ianevski A, Ghimire B, et al
    RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses.
    Leukemia. 2020 Aug 11. pii: 10.1038/s41375-020-01011.
    PubMed     Abstract available

  371. MIMS AS, Kohlschmidt J, Eisfeld AK, Mromicronzek K, et al
    Comparison of clinical and molecular characteristics of patients with acute myeloid leukemia and either TP73 or TP53 mutations.
    Leukemia. 2020 Aug 5. pii: 10.1038/s41375-020-1007.

  372. FURSTENAU M, Langerbeins P, De Silva N, Fink AM, et al
    COVID-19 among fit patients with CLL treated with venetoclax-based combinations.
    Leukemia. 2020;34:2225-2229.

  373. MACHOVA POLAKOVA K, Zizkova H, Zuna J, Motlova E, et al
    Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission.
    Leukemia. 2020;34:2113-2124.
    PubMed     Abstract available

  374. HEHLMANN R, Voskanyan A, Lauseker M, Pfirrmann M, et al
    High-risk additional chromosomal abnormalities at low blast counts herald death by CML.
    Leukemia. 2020;34:2074-2086.
    PubMed     Abstract available

  375. KAISER A, Schmidt M, Huber O, Frietsch JJ, et al
    SIRT7: an influence factor in healthy aging and the development of age-dependent myeloid stem-cell disorders.
    Leukemia. 2020;34:2206-2216.
    PubMed     Abstract available

    July 2020
  376. AUMANN WK, Heath JL, Conway AE, Sze SK, et al
    Fusion of the CRM1 nuclear export receptor to AF10 causes leukemia and transcriptional activation of HOXA genes.
    Leukemia. 2020 Jul 30. pii: 10.1038/s41375-020-0998.

  377. DEL GALY AS, Marouf A, Raffoux E, Robin M, et al
    Letter to the Editor: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality.
    Leukemia. 2020 Jul 30. pii: 10.1038/s41375-020-1004.

  378. TOSELLO V, Bongiovanni D, Liu J, Pan Q, et al
    Cross-talk between GLI transcription factors and FOXC1 promotes T-cell acute lymphoblastic leukemia dissemination.
    Leukemia. 2020 Jul 30. pii: 10.1038/s41375-020-0999.
    PubMed     Abstract available

  379. GASSNER FJ, Zaborsky N, Buchumenski I, Levanon EY, et al
    RNA editing contributes to epitranscriptome diversity in chronic lymphocytic leukemia.
    Leukemia. 2020 Jul 30. pii: 10.1038/s41375-020-0995.
    PubMed     Abstract available

  380. YUN S, Geyer SM, Komrokji RS, Al Ali NH, et al
    Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML).
    Leukemia. 2020 Jul 29. pii: 10.1038/s41375-020-0997.
    PubMed     Abstract available

  381. ANDERSEN MA, Moser CE, Lundgren J, Niemann CU, et al
    Correction: Epidemiology of bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal nation-wide cohort study.
    Leukemia. 2020 Jul 27. pii: 10.1038/s41375-020-0992.
    PubMed     Abstract available

  382. FANG C, Rao S, Crispino JD, Ntziachristos P, et al
    Determinants and role of chromatin organization in acute leukemia.
    Leukemia. 2020 Jul 20. pii: 10.1038/s41375-020-0981.
    PubMed     Abstract available

  383. PARTING O, Langer S, Kuepper MK, Wessling C, et al
    Therapeutic inhibition of FcgammaRIIb signaling targets leukemic stem cells in chronic myeloid leukemia.
    Leukemia. 2020 Jul 20. pii: 10.1038/s41375-020-0977.
    PubMed     Abstract available

  384. ANDERSEN MA, Rostgaard K, Niemann CU, Hjalgrim H, et al
    Antimicrobial use before chronic lymphocytic leukemia: a retrospective cohort study.
    Leukemia. 2020 Jul 20. pii: 10.1038/s41375-020-0980.
    PubMed     Abstract available

  385. JESTIN M, Tarfi S, Duchmann M, Badaoui B, et al
    Prognostic value of monocyte subset distribution in chronic myelomonocytic leukemia: results of a multicenter study.
    Leukemia. 2020 Jul 20. pii: 10.1038/s41375-020-0955.

  386. MALANI D, Yadav B, Kumar A, Potdar S, et al
    KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia.
    Leukemia. 2020 Jul 17. pii: 10.1038/s41375-020-0978.

  387. GRUBER E, Franich RL, Shortt J, Johnstone RW, et al
    Distinct and overlapping mechanisms of resistance to azacytidine and guadecitabine in acute myeloid leukemia.
    Leukemia. 2020 Jul 13. pii: 10.1038/s41375-020-0973.

  388. BROWN JR, Zelenetz A, Furman R, Lamanna N, et al
    Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib.
    Leukemia. 2020 Jul 12. pii: 10.1038/s41375-020-0974.

  389. TAMBE M, Karjalainen E, Vaha-Koskela M, Bulanova D, et al
    Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition.
    Leukemia. 2020 Jul 10. pii: 10.1038/s41375-020-0972.
    PubMed     Abstract available

  390. SCARFO L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, et al
    COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.
    Leukemia. 2020 Jul 9. pii: 10.1038/s41375-020-0959.
    PubMed     Abstract available

  391. ABECASIS M, Cross NCP, Brito M, Ferreira I, et al
    Is cancer latency an outdated concept? Lessons from chronic myeloid leukemia.
    Leukemia. 2020 Jul 6. pii: 10.1038/s41375-020-0957.
    PubMed     Abstract available

  392. OSTERGAARD A, Bohnstedt C, Grell K, Degn M, et al
    Acute lymphoblastic leukemia and down syndrome: 6-mercaptopurine and methotrexate metabolites during maintenance therapy.
    Leukemia. 2020 Jul 4. pii: 10.1038/s41375-020-0946.

  393. BAUMANN T, Delgado J, Montserrat E
    CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report.
    Leukemia. 2020;34:1954-1956.

  394. LI W, Wang D, Guo J, Yuan G, et al
    COVID-19 in persons with chronic myeloid leukaemia.
    Leukemia. 2020;34:1799-1804.
    PubMed     Abstract available

  395. REISSER T, Halbgebauer D, Scheurer J, Wolf L, et al
    In vitro-generated alloantigen-specific Th9 cells mediate antileukemia cytotoxicity in the absence of graft-versus-host disease.
    Leukemia. 2020;34:1943-1948.

  396. OSSENKOPPELE GJ, Breems DA, Stuessi G, van Norden Y, et al
    Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS.
    Leukemia. 2020;34:1751-1759.
    PubMed     Abstract available

  397. BLAKEMORE SJ, Clifford R, Parker H, Antoniou P, et al
    Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial.
    Leukemia. 2020;34:1760-1774.
    PubMed     Abstract available

  398. KIM R, Boissel N, Touzart A, Leguay T, et al
    Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation.
    Leukemia. 2020;34:1730-1740.
    PubMed     Abstract available

  399. GERNER RR, Macheiner S, Reider S, Siegmund K, et al
    Targeting NAD immunometabolism limits severe graft-versus-host disease and has potent antileukemic activity.
    Leukemia. 2020;34:1885-1897.
    PubMed     Abstract available

  400. HORNE GA, Stobo J, Kelly C, Mukhopadhyay A, et al
    A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease.
    Leukemia. 2020;34:1775-1786.
    PubMed     Abstract available

    June 2020
  401. GARCIA EG, Veloso A, Oliveira ML, Allen JR, et al
    PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis.
    Leukemia. 2020 Jun 30. pii: 10.1038/s41375-020-0937.
    PubMed     Abstract available

  402. PFIRRMANN M, Clark RE, Prejzner W, Lauseker M, et al
    The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia.
    Leukemia. 2020 Jun 29. pii: 10.1038/s41375-020-0931.
    PubMed     Abstract available

  403. JENSEN P, Carlet M, Schlenk RF, Weber A, et al
    Requirement for LIM kinases in acute myeloid leukemia.
    Leukemia. 2020 Jun 26. pii: 10.1038/s41375-020-0943.
    PubMed     Abstract available

  404. LOONTIENS S, Vanhauwaert S, Depestel L, Dewyn G, et al
    A novel TLX1-driven T-ALL zebrafish model: comparative genomic analysis with other leukemia models.
    Leukemia. 2020 Jun 26. pii: 10.1038/s41375-020-0938.

  405. CERRANO M, Duchmann M, Kim R, Vasseur L, et al
    Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy.
    Leukemia. 2020 Jun 24. pii: 10.1038/s41375-020-0932.
    PubMed     Abstract available

  406. KLOOS A, Mintzas K, Winckler L, Gabdoulline R, et al
    Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia.
    Leukemia. 2020 Jun 24. pii: 10.1038/s41375-020-0929.
    PubMed     Abstract available

  407. HOCHHAUS A, Gambacorti-Passerini C, Abboud C, Gjertsen BT, et al
    Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study.
    Leukemia. 2020 Jun 22. pii: 10.1038/s41375-020-0915.
    PubMed     Abstract available

  408. MOLICA S, Giannarelli D
    Prognostic models for chronic lymphocytic leukemia (CLL): a systematic review and meta-analysis.
    Leukemia. 2020 Jun 21. pii: 10.1038/s41375-020-0924.

  409. FERRARA F, Zappasodi P, Roncoroni E, Borlenghi E, et al
    Impact of Covid-19 on the treatment of acute myeloid leukemia.
    Leukemia. 2020 Jun 19. pii: 10.1038/s41375-020-0925.

  410. DAVI F, Langerak AW, de Septenville AL, Kolijn PM, et al
    Immunoglobulin gene analysis in chronic lymphocytic leukemia in the era of next generation sequencing.
    Leukemia. 2020 Jun 19. pii: 10.1038/s41375-020-0923.
    PubMed     Abstract available

  411. ALFAYEZ M, Issa GC, Patel KP, Wang F, et al
    The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia.
    Leukemia. 2020 Jun 19. pii: 10.1038/s41375-020-0920.
    PubMed     Abstract available

  412. BRECCIA M, Abruzzese E, Bocchia M, Bonifacio M, et al
    Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey.
    Leukemia. 2020 Jun 18. pii: 10.1038/s41375-020-0904.

  413. HAUER J, Fischer U, Auer F, Borkhardt A, et al
    Regional BCG vaccination policy in former East- and West Germany may impact on both severity of SARS-CoV-2 and incidence of childhood leukemia.
    Leukemia. 2020 Jun 18. pii: 10.1038/s41375-020-0871.

  414. MARCAIS A, Lhermitte L, Artesi M, Laurent C, et al
    Targeted deep sequencing reveals clonal and subclonal mutational signatures in Adult T-cell leukemia/lymphoma and defines an unfavorable indolent subtype.
    Leukemia. 2020 Jun 17. pii: 10.1038/s41375-020-0900.
    PubMed     Abstract available

  415. MAURO FR, Giannarelli D, Galluzzo CM, Vitale C, et al
    Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL).
    Leukemia. 2020 Jun 17. pii: 10.1038/s41375-020-0884.
    PubMed     Abstract available

  416. ISSA GC, Kantarjian HM, Xiao L, Ning J, et al
    Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality.
    Leukemia. 2020 Jun 16. pii: 10.1038/s41375-020-0916.
    PubMed     Abstract available

  417. POPOV A, Buldini B, De Lorenzo P, Disaro S, et al
    Prognostic value of minimal residual disease measured by flow-cytometry in two cohorts of infants with acute lymphoblastic leukemia treated according to either MLL-Baby or Interfant protocols.
    Leukemia. 2020 Jun 12. pii: 10.1038/s41375-020-0912.

  418. WONG RL, Ketcham M, Irwin T, Akilesh S, et al
    Donor-derived acute promyelocytic leukemia presenting as myeloid sarcoma in a transplanted kidney.
    Leukemia. 2020 Jun 10. pii: 10.1038/s41375-020-0903.

  419. NORSWORTHY KJ, Avagyan A, Bird ST, Li Y, et al
    Second cancers in adults with acute promyelocytic leukemia treated with or without arsenic trioxide: a SEER-medicare analysis.
    Leukemia. 2020 Jun 9. pii: 10.1038/s41375-020-0905.

  420. ECTOR GICG, Visser O, Westerweel PE, Janssen JJWM, et al
    Primary therapy and relative survival among elderly patients with chronic myeloid leukemia: a population-based study in the Netherlands, 1989-2017.
    Leukemia. 2020 Jun 8. pii: 10.1038/s41375-020-0902.

  421. YAN F, Wong NC, Powell DR, Curtis DJ, et al
    A 9-gene score for risk stratification in B-cell acute lymphoblastic leukemia.
    Leukemia. 2020 Jun 2. pii: 10.1038/s41375-020-0888.

  422. WANDER P, Cheung LC, Pinhanos SS, Jones L, et al
    Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia.
    Leukemia. 2020 Jun 2. pii: 10.1038/s41375-020-0895.

  423. MIMMI S, Maisano D, Nistico N, Vecchio E, et al
    Detection of chronic lymphocytic leukemia subpopulations in peripheral blood by phage ligands of tumor immunoglobulin B cell receptors.
    Leukemia. 2020 Jun 1. pii: 10.1038/s41375-020-0885.

  424. QUIJADA-ALAMO M, Hernandez-Sanchez M, Alonso-Perez V, Rodriguez-Vicente AE, et al
    CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition.
    Leukemia. 2020;34:1599-1612.
    PubMed     Abstract available

  425. MORSINK LM, Othus M, Bezerra ED, Wood BL, et al
    Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML.
    Leukemia. 2020;34:1577-1587.
    PubMed     Abstract available

  426. ZEIDNER JF, Knaus HA, Zeidan AM, Blackford AL, et al
    Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS.
    Leukemia. 2020;34:1563-1576.
    PubMed     Abstract available

  427. CAYE A, Rouault-Pierre K, Strullu M, Lainey E, et al
    Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment.
    Leukemia. 2020;34:1658-1668.
    PubMed     Abstract available

    May 2020
  428. ZINNGREBE J, Debatin KM, Fischer-Posovszky P
    Adipocytes in hematopoiesis and acute leukemia: friends, enemies, or innocent bystanders?
    Leukemia. 2020 May 30. pii: 10.1038/s41375-020-0886.
    PubMed     Abstract available

  429. EISFELD AK, Kohlschmidt J, Mims A, Nicolet D, et al
    Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years.
    Leukemia. 2020 May 27. pii: 10.1038/s41375-020-0872.
    PubMed     Abstract available

  430. MIDIC D, Rinke J, Perner F, Muller V, et al
    Prevalence and dynamics of clonal hematopoiesis caused by leukemia-associated mutations in elderly individuals without hematologic disorders.
    Leukemia. 2020 May 26. pii: 10.1038/s41375-020-0869.
    PubMed     Abstract available

  431. SHARF G, Marin C, Bradley JA, Pemberton-Whiteley Z, et al
    Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs.
    Leukemia. 2020 May 26. pii: 10.1038/s41375-020-0867.
    PubMed     Abstract available

  432. ROESSNER PM, Seiffert M
    T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?
    Leukemia. 2020 May 26. pii: 10.1038/s41375-020-0873.
    PubMed     Abstract available

  433. CARTEL M, Mouchel PL, Gotanegre M, David L, et al
    Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy.
    Leukemia. 2020 May 23. pii: 10.1038/s41375-020-0878.
    PubMed     Abstract available

  434. KUMAR R, Pereira RS, Zanetti C, Minciacchi VR, et al
    Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia.
    Leukemia. 2020 May 21. pii: 10.1038/s41375-020-0866.
    PubMed     Abstract available

  435. LAURENT AP, Kotecha RS, Malinge S
    Gain of chromosome 21 in hematological malignancies: lessons from studying leukemia in children with Down syndrome.
    Leukemia. 2020 May 20. pii: 10.1038/s41375-020-0854.
    PubMed     Abstract available

  436. BAMEZAI S, Demir D, Pulikkottil AJ, Ciccarone F, et al
    TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition.
    Leukemia. 2020 May 15. pii: 10.1038/s41375-020-0864.
    PubMed     Abstract available

  437. LORENTINO F, Labopin M, Ciceri F, Vago L, et al
    Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia.
    Leukemia. 2020 May 14. pii: 10.1038/s41375-020-0863.
    PubMed     Abstract available

  438. LUKAS M, Velten B, Sellner L, Tomska K, et al
    Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies.
    Leukemia. 2020 May 13. pii: 10.1038/s41375-020-0846.
    PubMed     Abstract available

  439. YOUNG KH
    Good prognosis or poor prognosis, dose-intensive or less intensive: who decides for adults with T-lymphoblastic lymphoma/leukemia.
    Leukemia. 2020 May 12. pii: 10.1038/s41375-020-0861.

  440. KARLSSON C, Akula MK, Staffas A, Cisowski J, et al
    Knockout of the RAS endoprotease RCE1 accelerates myeloid leukemia by downregulating GADD45b.
    Leukemia. 2020 May 12. pii: 10.1038/s41375-020-0859.

  441. PARIKH SA, Gale RP, Kay NE
    Chronic lymphocytic leukemia in 2020: a surfeit of riches?
    Leukemia. 2020 May 11. pii: 10.1038/s41375-020-0852.

  442. NAGLER A, Dholaria B, Labopin M, Savani BN, et al
    Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia.
    Leukemia. 2020 May 11. pii: 10.1038/s41375-020-0850.
    PubMed     Abstract available

  443. GARCIA-CANAVERAS JC, Lancho O, Ducker GS, Ghergurovich JM, et al
    SHMT inhibition is effective and synergizes with methotrexate in T-cell acute lymphoblastic leukemia.
    Leukemia. 2020 May 7. pii: 10.1038/s41375-020-0845.
    PubMed     Abstract available

  444. HOCHHAUS A, Breccia M, Saglio G, Garcia-Gutierrez V, et al
    Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors.
    Leukemia. 2020 May 4. pii: 10.1038/s41375-020-0842.
    PubMed     Abstract available

  445. JOSHI SK, Keck JM, Eide CA, Bottomly D, et al
    ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia.
    Leukemia. 2020 May 4. pii: 10.1038/s41375-020-0844.

  446. BAMOPOULOS SA, Batcha AMN, Jurinovic V, Rothenberg-Thurley M, et al
    Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia.
    Leukemia. 2020 May 1. pii: 10.1038/s41375-020-0839.
    PubMed     Abstract available

  447. REICH D, Kresinsky A, Muller JP, Bauer R, et al
    SHP1 regulates a STAT6-ITGB3 axis in FLT3ITD-positive AML cells.
    Leukemia. 2020;34:1444-1449.

  448. DUPLOYEZ N, Goursaud L, Fenwarth L, Bories C, et al
    Familial myeloid malignancies with germline TET2 mutation.
    Leukemia. 2020;34:1450-1453.

  449. DEB G, Wingelhofer B, Amaral FMR, Maiques-Diaz A, et al
    Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia.
    Leukemia. 2020;34:1266-1277.
    PubMed     Abstract available

  450. RODRIGUEZ S, Abundis C, Boccalatte F, Mehrotra P, et al
    Therapeutic targeting of the E3 ubiquitin ligase SKP2 in T-ALL.
    Leukemia. 2020;34:1241-1252.
    PubMed     Abstract available

  451. SCHNEIDER E, Pochert N, Ruess C, MacPhee L, et al
    MicroRNA-708 is a novel regulator of the Hoxa9 program in myeloid cells.
    Leukemia. 2020;34:1253-1265.
    PubMed     Abstract available

    April 2020
  452. TOMLINSON CG, Sasa G, Aubert G, Martin-Giacalone B, et al
    Clinical and functional characterization of telomerase variants in patients with pediatric acute myeloid leukemia/myelodysplastic syndrome.
    Leukemia. 2020 Apr 21. pii: 10.1038/s41375-020-0835.

  453. DHAKAL B, Patel S, Girnius S, Bachegowda L, et al
    Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era.
    Leukemia. 2020 Apr 20. pii: 10.1038/s41375-020-0830.
    PubMed     Abstract available

  454. WAKAMATSU M, Okuno Y, Murakami N, Miwata S, et al
    Detection of subclonal SETBP1 and JAK3 mutations in juvenile myelomonocytic leukemia using droplet digital PCR.
    Leukemia. 2020 Apr 20. pii: 10.1038/s41375-020-0817.

  455. ELSAYED AH, Rafiee R, Cao X, Raimondi S, et al
    Correction: A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia.
    Leukemia. 2020 Apr 16. pii: 10.1038/s41375-020-0822.
    PubMed     Abstract available

  456. GENTILE M, Morabito F, Del Poeta G, Mauro FR, et al
    Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.
    Leukemia. 2020 Apr 14. pii: 10.1038/s41375-020-0833.

  457. THASTRUP M, Marquart HV, Levinsen M, Grell K, et al
    Correction: Flow cytometric detection of leukemic blasts in cerebrospinal fluid predicts risk of relapse in childhood acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology study.
    Leukemia. 2020 Apr 8. pii: 10.1038/s41375-020-0821.
    PubMed     Abstract available

  458. CORTES JE, Jiang Q, Wang J, Weng J, et al
    Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study.
    Leukemia. 2020 Apr 7. pii: 10.1038/s41375-020-0805.
    PubMed     Abstract available

  459. GODFREY L, Crump NT, O'Byrne S, Lau IJ, et al
    H3K79me2/3 controls enhancer-promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells.
    Leukemia. 2020 Apr 2. pii: 10.1038/s41375-020-0808.
    PubMed     Abstract available

  460. RUZICKA M, Koenig LM, Formisano S, Boehmer DFR, et al
    RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade.
    Leukemia. 2020;34:1017-1026.
    PubMed     Abstract available

  461. WINICK N, Martin PL, Devidas M, Shuster J, et al
    Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children's Oncology Group Studies P9904 and P9905.
    Leukemia. 2020;34:1006-1016.
    PubMed     Abstract available

  462. HOECHSTETTER MA, Busch R, Eichhorst B, Buhler A, et al
    Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group.
    Leukemia. 2020;34:1038-1051.
    PubMed     Abstract available

  463. FEDER K, Edmaier-Schroger K, Rawat VPS, Kirsten N, et al
    Differences in expression and function of LEF1 isoforms in normal versus leukemic hematopoiesis.
    Leukemia. 2020;34:1027-1037.
    PubMed     Abstract available

  464. REN Z, Shrestha M, Sakamoto T, Melkman T, et al
    Opposing effects of NPM1wt and NPM1c mutants on AKT signaling in AML.
    Leukemia. 2020;34:1172-1176.

  465. NAGLER A, Dholaria B, Labopin M, Socie G, et al
    The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation.
    Leukemia. 2020;34:1144-1153.
    PubMed     Abstract available

  466. KHAN HM, Gardner KM, Shaw C, Halpern AB, et al
    Need for routine examination of left ventricular ejection fraction in patients with AML.
    Leukemia. 2020;34:1169-1171.

  467. ASNANI M, Hayer KE, Naqvi AS, Zheng S, et al
    Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19.
    Leukemia. 2020;34:1202-1207.

    March 2020
  468. HEROLD T, Rothenberg-Thurley M, Grunwald VV, Janke H, et al
    Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.
    Leukemia. 2020 Mar 30. pii: 10.1038/s41375-020-0806.
    PubMed     Abstract available

  469. MONTALBAN-BRAVO G, Class CA, Ganan-Gomez I, Kanagal-Shamanna R, et al
    Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes.
    Leukemia. 2020;34:872-881.
    PubMed     Abstract available

  470. TATSUMI G, Kawahara M, Yamamoto R, Hishizawa M, et al
    LSD1-mediated repression of GFI1 super-enhancer plays an essential role in erythroleukemia.
    Leukemia. 2020;34:746-758.
    PubMed     Abstract available

  471. BURGER JA, Barr PM, Robak T, Owen C, et al
    Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.
    Leukemia. 2020;34:787-798.
    PubMed     Abstract available

  472. HERBRUEGGEN H, Mueller S, Rohde J, Arias Padilla L, et al
    Treatment and outcome of IG-MYC(+) neoplasms with precursor B-cell phenotype in childhood and adolescence.
    Leukemia. 2020;34:942-946.

    February 2020
  473. TIAN XP, Xie D, Huang WJ, Ma SY, et al
    A gene-expression-based signature predicts survival in adults with T-cell lymphoblastic lymphoma: a multicenter study.
    Leukemia. 2020 Feb 20. pii: 10.1038/s41375-020-0757.
    PubMed     Abstract available

  474. RADIVOYEVITCH T, Weaver D, Hobbs B, Maciejewski JP, et al
    Do persons with chronic myeloid leukaemia have normal or near normal survival?
    Leukemia. 2020;34:333-335.

  475. LANCE A, Druhan LJ, Vestal CG, Steuerwald NM, et al
    Altered expression of CSF3R splice variants impacts signal response and is associated with SRSF2 mutations.
    Leukemia. 2020;34:369-379.
    PubMed     Abstract available

  476. CHATURVEDI A, Goparaju R, Gupta C, Weder J, et al
    In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site.
    Leukemia. 2020;34:416-426.
    PubMed     Abstract available

  477. CHAO AK, Meyer JA, Lee AG, Hecht A, et al
    Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing.
    Leukemia. 2020;34:662-666.

  478. INNES AJ, Woolley P, Szydlo RM, Lozano S, et al
    Complete remission with incomplete count recovery (CRi) prior to allogeneic HCT for acute myeloid leukaemia is associated with a high non-relapse mortality.
    Leukemia. 2020;34:667-670.

  479. SKANLAND SS, Cremaschi A, Bendiksen H, Hermansen JU, et al
    An in vitro assay for biomarker discovery and dose prediction applied to ibrutinib plus venetoclax treatment of CLL.
    Leukemia. 2020;34:478-487.
    PubMed     Abstract available

    January 2020
  480. RASHIDI A, Kaiser T, Graiziger C, Holtan SG, et al
    Specific gut microbiota changes heralding bloodstream infection and neutropenic fever during intensive chemotherapy.
    Leukemia. 2020;34:312-316.

  481. KANDA J, Hayashi H, Ruggeri A, Kimura F, et al
    Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study.
    Leukemia. 2020;34:128-137.
    PubMed     Abstract available

  482. CUTLER JA, Udainiya S, Madugundu AK, Renuse S, et al
    Integrative phosphoproteome and interactome analysis of the role of Ubash3b in BCR-ABL signaling.
    Leukemia. 2020;34:301-305.

  483. GILLEECE MH, Labopin M, Savani BN, Yakoub-Agha I, et al
    Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT.
    Leukemia. 2020;34:87-99.
    PubMed     Abstract available

  484. BISAILLON R, Moison C, Thiollier C, Krosl J, et al
    Genetic characterization of ABT-199 sensitivity in human AML.
    Leukemia. 2020;34:63-74.
    PubMed     Abstract available

  485. YOSIFOV DY, Idler I, Bhattacharya N, Reichenzeller M, et al
    Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL.
    Leukemia. 2020;34:115-127.
    PubMed     Abstract available

    October 2019
  486. YOUNG KH
    Hematopoietic stem cell transplantation for adults with T-cell lymphoblastic lymphoma: can we successfully step into the era of precision medicine?
    Leukemia. 2019 Oct 22. pii: 10.1038/s41375-019-0608.

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.